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Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a recently characterized
cancer syndrome which predisposes to cutaneous and uterine leiomyomas as well as
renal cell carcinoma (RCC). Uterine leiomyosarcoma (ULMS) has also been observed
in certain Finnish HLRCC families. The predisposing gene for this syndrome, fumarate
hydratase (FH), was identified in 2002. The well-known function of FH is in the
tricarboxylic acid cycle (TCAC) in the energy metabolism of cells. As FH is a novel
cancer gene, the role of FH mutations in tumours is in general unknown. Similarly, the
mechanisms through which defective FH is associated with tumourigenesis are unclear.
The  loss  of  a  wild  type  allele  has  been  observed  in  virtually  all  HLRCC  patients
tumours and the FH enzyme activities are either totally lost or remarkably reduced in
the tissues of mutation carrier patients. Therefore, FH is assumed to function as a
tumour suppressor.
Mutations in genes encoding subunits of other TCAC enzyme SDH have also been
reported recently in tumours: mutations in SDHB, SDHC, and SDHD genes predispose
to paraganglioma and pheochromocytoma.
In the present study, mutations in the SDHB gene were observed to predispose to RCC.
This was the first time that mutations in SDHB have been detected in extra-paraganglial
tumours. Two different SDHB mutations were observed in two unrelated families. In the
first  family,  the  index  patient  was  diagnosed  with  RCC  at  the  age  of  24  years.
Additionally, his mother with a paraganglioma (PGL) of the heart and his maternal
uncle with lung cancer were both carriers of the mutation. The RCC of the index patient
and the PGL of his mother showed LOH. In the other family,  an SDHB mutation was
detected in two siblings who were both diagnosed with RCC at the ages of 24 and 26
years.  One  of  the  siblings  also  suffered  PGL.  All  these  tumours  showed  LOH.
Therefore, we concluded that mutations in SDHB predispose also for RCC in certain
families.
Several tumour types were analysed for FH mutations  to  define  the  role  of FH
mutations in these tumour types. In addition, patients with a putative cancer phenotype
were analysed to identify new HLRCC families. Three FH variants were detected, of
which  two  were  novel.  One  of  the  variants  was  observed  in  a  patient  diagnosed  with
ULMS at the age of 41 years. However, LOH was not detected in the tumour tissue. The
FH enzyme activity of the mutated protein was clearly reduced, being 43% of the
activity  of  the  normal  protein.  Together  with  the  results  from  an  earlier  study  we
calculated that the prevalence of FH mutations in Finnish non-syndromic ULMS is
around 2.4%. Therefore, FH mutations seem to have a minor role in the pathogenesis on
non-syndromic ULMS. Two other germline variants were detected in a novel tumour
type, ovarian mucinous cystadenoma. However, tumour tissues of the patients were not
available for LOH studies and therefore LOH status remained unclear. Therefore, it is
possible that FH mutations predispose also for ovarian tumours but further studies are
needed to verify this result.
A novel variant form of the FH gene  (FHv) was identified and characterized in more
detail. FHv contains an alternative first exon (1b), which appeared to function as 5’
UTR sequence. The translation of FHv is initiated in vitro from exons  two and  three.
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The localization of FHv is both cytosolic and nuclear, in contrast to the localization of
FH in mitochondria. FHv is expressed at low levels in all human tissues. Interestingly,
the expression was induced after heat shock treatment and in chronic hypoxia.
Therefore, FHv might have a role e.g. in the adaptation to unfavourable growth
conditions. However, this remains to be elucidated.
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1 REVIEW OF THE LITERATURE
1.1 Cancer is a genetic disease
Cancer is a disease which is characterized by unregulated growth of cells. In fact, cancer
is not one disease but a group of diseases, with different symptoms, origins, phenotypes,
and prognoses. To date, approximately 110 different types of human cancer have been
characterized (Weinberg 2007).
 The aberrant growth that characterizes cancer is caused by mutations in the DNA of the
cells. The accumulation of these mutations in the cell results in a state where the cell is
unable to control its own growth and proliferation and becomes cancerous. Recently, it
has been proposed that there are six features typical for almost all cancerous cells.
These features include the self-sufficiency in growth stimulating signals, insensitivity to
growth inhibiting signals, ability to avoid apoptosis and to replicate limitlessly, as well
as the capacity to induce angiogenesis and to metastasize (Hanahan and Weinberg
2000). These features are consequences of the accumulation of mutations in the genes
which regulate the proliferation, growth, differentiation, and programmed death of the
cell. To date, over 290 cancer genes have been identified (for a rewiev, see Futreal et al.
2004). However, the number will probably increase in the near future. Recently,
Sjöblom et al. (2006) investigated mutated genes in breast and colorectal cancers and
detected 189 mutated genes in these tumours. The vast majority of the mutated genes
had not previously been characterized as cancer genes. Cancer genes can be classified
into two subgroups: oncogenes and tumour suppressor genes.
1.1.1 Oncogenes
Oncogenes were discovered for the first time in the 1970s when Stehelin and his
colleagues perceived that a DNA sequence related to chicken sarcoma transforming
virus is present also in the genome of normal chicken cells (Stehelin et al. 1976).
However, the first human oncogene with a point mutation, HRAS, was not reported until
1982 (Reddy et al. 1982). Oncogenes are mutated forms of the cells’ normal
counterparts, proto-oncogenes. These genes typically regulate the growth of the cell in a
promoting manner or the death of the cell in a diminishing manner. Oncogenes encode,
for example, growth factors, growth factor receptors, transcription factors, or
intracellular signalling proteins. Mutations in these genes lead to abnormally active
function of the protein. The activation of proto-oncogenes can occur through point
mutations, gene amplifications, or chromosomal translocations (for a review, see Bishop
1991). Oncogenes behave dominantly at the cellular level: an activating mutation in one
of the two alleles is sufficient to promote tumourigenesis (for a review, see
Bishop1991).
Over one hundred oncogenes have been identified thus far (Futreal et al. 2004). The
RAS genes, KRAS, HRAS, and NRAS, are the most often mutated genes in human
cancers (Giehl 2005, Bos 1989). RAS genes encodes proteins that act as intracellular
signal transducers. Mutated forms of these proteins are constitutively activated. The
majority of mutated oncogenes occur in somatic cancers, but a few exceptions exist.
Germline mutations in the MET oncogene have been reported in patients diagnosed with
hereditary papillary renal carcinoma (HPRC, OMIM 605074, Schmidt et al. 1997). MET
encodes a receptor of the hepatocyte growth factor (HGF) (Bottaro et al. 1991).
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Germline mutations in RET predispose to multiple endocrine neoplasia type 2 (MEN2,
OMIM 171400, Mulligan et al. 1993). RET oncogene encodes a tyrosine kinase
receptor. Germline mutations in the KIT oncogene predispose to familial gastrointestinal
stromal tumour syndrome (GIST, OMIM 606764, Nishida et al. 1998) and KIT
functions as a transmembrane tyrosine kinase. Oncogenic mutations in MET, RET or
KIT leads to the constitutive activation of the corresponding receptor (Schmidt et al.
1997, Salvatore et al. 2000). Mutations in the CDK4 oncogene  predispose  to  familial
malignant melanoma (FMM, OMIM 609048, Zuo et al. 1996). CDK4 is involved in the
control of cell proliferation during the G1 phase in the cell cycle (Harbour et al. 1999).
1.1.2 Tumour suppressor genes
Tumour suppressor genes regulate the growth of the cells by inhibiting growth or
promoting death (Kinzler and Vogelstein 1997). Products of these genes affect a wide
variety of cellular functions and the general role of these proteins is to reduce the
likelihood that the cell would escape normal growth and proliferation control and
became cancerous. At the cellular level tumour suppressor genes are recessive, which
means that both alleles must be mutated for the gene to be inactivated (Kinzler and
Vogelstein 1997). The idea of biallelic inactivation of tumour suppressor genes was first
proposed by Alfred Knudson in 1971, when he presented his famous two-hit hypothesis
(Knudson 1971). He studied the kinetics of the appearance of unilateral or bilateral
retinoblastoma and concluded that these conditions are related: mutations in both alleles
of cancer predisposing gene are needed for tumourigenesis. In the inherited form of
retinoblastoma one mutated allele is inherited and a single additional mutation is
sufficient for tumour formation, while in the sporadic form of the disease two somatic
events are needed. However, the fact that those two events occur in two copies of the
RB1 gene was understood only later (Cavenee et al. 1983, Friend et al. 1986).
Tumour suppressor genes can be divided into three subclasses according to their
functions: gatekeepers, caretakers and landscapers (Kinzler and Vogelstein 1997, 1998).
Gatekeepers are genes which are involved in the direct regulation of the proliferation,
differentiation, or apoptosis of the cell. Biallelic inactivation of a gatekeeper gene could
directly promote the growth of a tumour. This subgroup includes e.g. the two most
common tumour suppressor genes, RB1 and TP53, whose pathways are mutated in
almost all tumours (for a review, see Knudson 2002). RB1 functions as a key regulator
of the cell cycle. Inactivation of RB1 allows a cell enter to S-phase even if the DNA is
unrepaired, which leads to abnormally high proliferation rates. Germline mutations in
RB1 predispose to sarcomas in addition to retinoblastoma of childhood (OMIM
180200). TP53 encodes tumour protein 53 (p53) which, in turn, controls for example
the  quality  of  the  DNA  and  arrests  the  cell  cycle  or  induces  apoptosis  if  the  DNA  is
damaged. If p53 is inactivated, cells are able to proliferate even before the DNA has
been repaired. Germline mutations in TP53 cause Li-Fraumeni syndrome (OMIM
151623), in which patients have increased risk for sarcomas and breast cancer (Malkin
et al. 1990). In addition, it has been estimated that TP53 exists  in  the  mutated  form in
half of all human tumours (Weinberg et al. 2007). Caretakers, in turn, maintain the
integrity of the genome and regulate the number of mutations accumulating in the
genome of a cell (Kinzler and Vogelstein 1997). This group includes genes such as
MHS2, MLH1 and XP which are involved, for example, in the recognition and repair of
damaged DNA. The inactivation of a caretaker gene does not directly lead to growth
promotion but to genomic instability, which results in increased mutation rates for all
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genes, including tumour suppressors and oncogenes (Kinzler and Vogelstein 1997).
Landscapers are genes which are involved in the maintenance of the cellular
microenvironment (Kinzler and Vogelstein 1998). Mutations in these genes can enable
the development of the tumour, for example, by offering suitable growth conditions via
abnormal stromal cells.
The majority of the hereditary cancer syndromes are caused by inherited mutations in
tumour suppressor genes (for a review, see Knudson 2002). While one allele of a
tumour suppressor gene is inactivated in all cells of the individual, only one somatic
alteration is needed to completely lose the function of the gene. Therefore, the risk of
developing tumours is higher for patients with germline mutations and the onset of the
disease usually occurs at younger age than in general population. Inherited mutations in
tumour suppressor genes are usually small alterations, such as point mutations, or short
deletions or insertions. In contrast, somatic inactivation of the second allele (loss of
heterozygosity, LOH) occurs more commonly via larger alterations such as deletion of
the  whole  chromosome  or  chromosome  arm,  or  via  mitotic  recombination  or  gene
conversion (Weinberg 2007).
1.1.3 Epigenetic and environmental factors
DNA mutations leading to alterations in the structure of oncogenes or tumour
suppressor genes have been considered as the main factors in tumourigenesis. However,
also epigenetic factors, which have no direct impact on the DNA sequence, could affect
the activation or inactivation of cancer related genes. These epigenetic factors include
non-coding or microRNAs, hypo- or hypermethylation of the DNA, post-translational
modification  of  the  histones,  and  remodeling  of  the  nucleosomes  (O’Donnell  et  al.
2005, for a review, see Ducasse and Brown 2006).
DNA methylation is considered as the most common epigenetic alteration associated
with the carcinogenesis. Either hypomethylation or hypermethylation have been
observed in all types of cancer cells examined thus far (for a review, see Ducasse and
Brown 2006).  DNA methylation occurs at cytosines of CpG-rich regions of the
genome.  The  addition  of  methyl  groups  to  the  cytosines  at  a  promoter  region  can
prevent the binding of transcription factors or polymerase to the promoter, and further
lead  to  the  silencing  of  a  tumour  suppressor  gene.  In  several  studies,  however,  DNA
hypermethylation appears to affect mainly genes that are already suppressed (Bird
2002). Conversely, absence of appropriate methylation at the promoter region of an
oncogene can lead to the abnormal activation of the gene. The other epigenetic factors
contribute at least to the transcription of genes, the maintenance and regulation of
chromatin structure, and the stability of the genome (for a review, see Ducasse and
Brown 2006).
In addition to genetic and epigenetic factors, several environmental factors are known to
contribute to tumourigenesis. These factors include e.g. exposure to UV-radiation or
carcinogenic chemicals, and tobacco smoking. However, environmental factors do not
directly cause cancer but instead increase the mutation rate in the DNA. This results in
accumulation of mutations and thus an increased risk of cancer.
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1.1.4 Cancer is a multistep process
Tumourigenesis originates from the accumulation of mutations in the genome of a
single cell through which the cell acquires a growth advantage over the surrounding
cells. The process proceeds after additional mutations occur in the descendant cells
leading these cells towards cancerous growth. This clonal and multistep process leads to
the  situation  in  which  all  cells  of  a  tumour  are  descendants  of  a  single  ancestor  cell.
However, these cells within a tumour mass are not identical, since different mutations
occur in different cells by chance during tumourigenesis (figure 1).
Figure 1. Clonal diversification through random mutations. All cells in a tumour are
descendants of a single ancestor cell. However, these cells are not identical due to the
random mutations occurring in each cell. Modified from Weinberg 2007.
The exact number of genetic alterations needed for carcinogenesis is unknown. It has
been estimated that approximately four to seven functionally important changes would
be needed for tumourigenesis (Renan 1993). Hanahan and Weinberg (2000) have
suggested that changes in six distinct cellular regulatory pathways are needed to
transform  a  normal  human  cell  to  a  tumourigenic  one  (see  section  1.1).  They  assume
that virtually all tumours have to acquire alterations in these pathways, but the
localization of the change along the pathway and the order of which these changes are
acquired vary. However, Sjöblom et al. (2006) recently analysed over 13 000 protein
encoding genes in breast and colorectal carcinomas and detected on average 90 mutated
genes in individual tumours. On average, 11 genes per tumour were mutated at
significant frequencies, and the remaining mutations were probably so-called passenger
mutations, which do not contribute to tumourigenesis (Sjöblom et al. 2006). The
accumulation of mutations in genes, which regulate the proliferation of the cell and
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control the quality of the DNA leads to the instability of the genome of cancer cell. This
results in aberrant karyotypes and abnormally high mutation rates observed in tumours
and can explain the high number of passenger mutations.
The multistep progression of cancer has been studied in more detail in colorectal cancer,
and a famous model called the adenoma-carcinoma sequence has been established
(Fearon and Vogelstein, 1990, Kinzler and Vogelstein, 1996). According to this model,
the progression of the disease begins from normal epithelium and proceeds to
carcinoma through adenomatous stages, which are characterized by the accumulation of
aberrations in the cells (Figure 2). These aberrations include inactivation of tumour
suppressor genes and activation of oncogenes, as well as epigenetic factors such as
DNA hypomethylation.
Figure 2. Adenoma-carcinoma sequence. The transformation of a normal epithelium
to carcinoma occurs through adenomatous stages. This multistep process is
characterized by inactivation of tumour suppressor genes (APC, TP53, SMAD4),
activation of oncogenes (KRAS), and epigenetic factors such as DNA hypomethylation.
Adapted from Kinzler and Vogelstein (1996) and Weinberg (2007).
1.1.5 Tumour stem cells
The very first idea of tumour stem cells was proposed in 1875, when Cohnheim
suggested that cancer might arise from a small population of cells with stem cell like
properties. Since then, several studies have indicated that a single tumour cell can be
enough to generate a new tumour and accumulating evidence suggests the notion that
tumour  stem  cells  exist  (for  a  review,  see  Polyak  and  Hahn  2006).  According  to  this
idea, tumour tissue contains a small population of stem cells with unlimited self-renewal
capacity and tumourigenic potential. The great majority of tumour forming cells are
fully or partially differentiated cells which can proliferate only a limited number of
times and lack the ability to recreate a tumour. Results from several studies support the
idea that tumours contain cells with stem cell properties: A small population of tumour
cells which displays stem cell markers at their surface could transfer leukemia or breast
cancer into mice, whereas thousands of fold higher numbers of cells lacking these cell
surface markers could not (Dick et al. 1997, Al-Hajj et al. 2003). It has been proposed
that all tumours origin from cancer stem cells and several models have been proposed
for tumour stem cell development. In the first model, a mutation that affects asymmetric
cell division occurs in a normal stem cell disrupting the regulation of asymmetric
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division and leading to increased numbers of stem cells. These mutated stem cells
acquire additional mutations and become cancer stem cells. In the second model,
mutations have accumulated in one stem cell which is transformed to a malignant
cancer stem cell. In the third model, a fully or partly differentiated cell acquires
mutations which lead it toward a dedifferentiated state e.g. through an epithelial-
mesenchymal  transition.  The  cell  mimics  tumour  stem cells  but  it  is  not  a  true  cancer
stem cell. While the origin of tumour stem cells is not unambiguous, evidence
supporting all three hypotheses exists (for a review, see Polyak and Hahn 2006). In any
case, if only a small number of tumour forming cells are capable of proliferating
limitlessly, the mutation rate must be higher than earlier expected. However, the
accumulation of mutations in cells leads to instability of the genome and further
increases the mutation rate.
1.2 Renal cell carcinoma
Renal cell cancer (RCC) accounts for approximately 2-3% of all human cancer cases
worldwide, and it appears that the incidence of RCC will increase (Kopper and Timar
2006, McLaughlin and Lipworth 2000). In Finland, approximately 750 new RCC cases
are diagnosed annually, which accounts for 2.9% of all cancer cases (Finnish Cancer
Registry 2005, Cancer statistics on the Finnish Cancer Registry web page  last updated
on 20th Sep 2006). As for cancer in general, RCC is not a single disease but a disease
with several different morphological subtypes. The most common subtype is clear cell
(conventional) RCC accounting for approximately 80% of cases. This is followed by
papillary RCC (approximately 15% of cases), chromophobe RCC (approximately 5% of
cases), collecting duct RCC (less than 1%), and unclassified RCCs (less than 2%;
Kopper and Timar 2006). RCC occurs typically between 50 and 70 years of age, and is
more common among men than women. The majority of  RCC cases are sporadic, while
hereditary forms of RCC account for less than 3% of all cases (for a review, see Kopper
and Timar 2006).
1.2.1 Hereditary cancer syndromes with predisposition to renal cell carcinoma
1.2.1.1 Hereditary leiomyomatosis and renal cell cancer
In 1973, Reed and colleagues described for the first time a young patient with renal cell
carcinoma, uterine leiomyosarcoma and cutaneous leiomyomas. The first degree
relatives of this patient were also diagnosed with leiomyomas (Reed et al. 1973,
Engelke and Christophers 1979). However, it took over two decades until these features
were understood to be features of one syndrome. In 2001, a novel cancer predisposing
syndrome  was  characterized  with  a  predisposition  to  skin  and  uterine  leiomyomas
(ULM), RCC, and ULMS (Launonen et al. 2001). This syndrome was named hereditary
leiomyomatosis and renal cell cancer (HLRCC, OMIM 605839), and the disease gene
was genetically mapped to chromosome 1q42-q44 (Launonen et al. 2001).
Concurrently, another research group described a similar syndrome with predisposition
only to skin and uterine leiomyomas. This syndrome was named multiple cutaneous and
uterine leiomyomata (MCUL, OMIM 150800), and the predisposing gene was mapped
to  the  same  chromosomal  locus  as  HLRCC  (Alam  et  al.  2001).  In  fact,  these  two
syndromes  were  variants  of  the  same  disease  with  slightly  different  phenotypes.  This
was ascertained since the predisposing gene for both conditions was identified as
fumarate hydratase (FH, fumarase) (Tomlinson et al., 2002). Since 2001, altogether
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137 HLRCC families have been characterized worldwide. FH mutations  have  been
reported in 89% of these families (122 out of 137 families) (Launonen et al. 2001, Kiuru
et al. 2001, Kiuru et al. 2002, Alam et al. 2003, Martinez-Mir et al. 2003, Toro et al.
2003, Chan et al. 2005, Chuang et al. 2005, Kim 2005, Badeloe et al. 2006, Chuang et
al. 2006, Lehtonen et al. 2006, Lehtonen et al. 2007, Varol et al. 2006, Wei et al. 2006).
HLRCC is inherited dominantly and LOH has been observed in almost all tumours,
indicating that FH functions as a tumour suppressor gene (Kiuru and Launonen 2004,
Tomlinson et  al.  2002).  The majority of patients carrying FH mutations are diagnosed
with benign skin or uterine leiomyomas. The penetrance of skin or uterine leiomyomas
among HLRCC patients with FH mutation is high, being approximately 85-89% (Alam
et al. 2005c, Kiuru and Launonen 2004). Although these lesions are benign, they may
cause difficult symptoms. There may be multiple skin leiomyomas and they may be
painful. The uterine leiomyomas cause pain and bleeding, and are the most common
reason for hysterectomy among women of fertile age.
In addition to benign leiomyomas, a minority of patients carrying FH mutations are
predisposed to very aggressive RCC and ULMS. Both of these malign tumour types
occur  at  especially  young  ages.  The  age  of  onset  of  the  disease  varies  from  16  to  90
years in RCC and from 27 to 39 years in ULMS, while the median ages are 40.5 and 32,
respectively (Lehtonen et al. 2006, Alam et al. 2005c). In addition to the exceptionally
early onset, renal tumours in HLRCC families display unusual histologies. While the
majority of the tumours display papillary type 2 histology, two tumours have been
classified as collecting duct RCCs and one tumour as conventional (clear cell) RCC
(Launonen et al. 2001, Alam et al. 2003, Toro et al. 2003, Chan et al. 2005, Badeloe et
al. 2006, Lehtonen et al. 2007, Wei et al. 2006). In addition, the existence of renal
tumours in HLRCC is typically unilateral, which is in contrast to the other hereditary
RCC syndromes such as VHL and HPRC (see section 1.2.1.2). The penetrance of RCC
and ULMS among FH mutation carriers is reduced, while RCC is observed in only 21%
and ULMS in 2.5% of mutation positive HLRCC families (26 and 3 families out of 122
families, respectively) (Launonen et al. 2001, Kiuru et al. 2001, Kiuru et al. 2002, Alam
et al. 2003, Martinez-Mir et al. 2003, Toro et al. 2003, Chan et al. 2005, Chuang et al.
2005, Kim 2005, Badeloe et al. 2006, Chuang et al. 2006, Lehtonen et al. 2006,
Lehtonen et al. 2007, Varol et al. 2006, Wei et al. 2006). However, the risk of both RCC
and ULMS is increased in the Finnish HLRCC families (Lehtonen et al. 2006). While
RCC has been diagnosed in 71% of Finnish families (5 out of 7 families) compared to
in 21% of HLRCC families worldwide, ULMS has been observed only in the Finnish
families  (3  out  of  7  families,  43%).  The  sites  or  types  of  the FH mutations do not
explain these differences in the occurrence of malignancies between populations, since
mutation spectrum among families overlaps (see section 1.4.3).  In addition to these
characteristic tumours, several other tumour types have also infrequently been observed
in HLRCC families. These tumour types include both malign and benign tumours such
as breast carcinoma, prostate cancer, bladder carcinoma, hematological malignancies,
testis  leydig  cell  tumours,  atypical  uterine  leiomyomas,  ovarian  and  kidney  cysts,  and
adrenal gland adenomas (Kiuru and Launonen 2004, Carvajal-Carmona et al. 2006,
Lehtonen et al. 2006, 2007, Varol et al. 2006). However, at least some of these tumour
types are propably observed by chance and are not caused by FH mutations.
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1.2.1.2 Other hereditary syndromes with predisposition to renal cell carcinoma
Von Hippel-Lindau syndrome (VHL, OMIM 193300) is the most common hereditary
RCC syndrome. The earliest reports concerning this syndrome were published in the
beginning of the 20th century by Von Hippel (1904) and Lindau (1927). The current
form of the VHL syndrome was characterized in 1964 by Melmon and Rosen. The most
common features of VHL are retinal, cerebellar, and spinal hemangioblastoma
occurring in approximately 60% of the patients (Maddock et al. 1996). Bilateral clear
cell RCC occurs in approximately 25-45% of the patients and pheochromocytoma
(PCC) in 15%. VHL has been classified as types 1 and 2 based on whether PCC exists
(type 2) or not (type 1) (Neumann and Wiestler 1991). VHL type 2 has further been
divided into type 2A (with PCC), and 2B (with PCC and RCC) (Brauch et al. 1995).
VHL syndrome is caused by heterozygous germline mutations in the VHL gene located
at chromosome 3p25-p26 (Latif et al. 1993). Tumours of the patients typically display
somatic  loss  of  the  wild  type  allele  or  hypermethylation  at  the VHL locus, indicating
that VHL functions as a tumour suppressor gene (Crossey et al. 1994, Prowse et al.
1997). Different germline mutations in VHL cause different phenotypes: deletions,
insertions and nonsense mutations are associated with VHL with RCC and without
PCC,  whereas  missense  mutations  are  associated  with  VHL  with  PCC  (Chen  et  al.
1995, Zbar et al 1996). VHL mutations have also been observed in the majority
(approximately 70%) of sporadic RCCs.
The VHL protein (pVHL) functions as a regulator of the critical transcription factor
termed hypoxia-inducible factor1 (HIF1) (Iliopoulos et al. 1996, Maxwell et al. 1999).
HIF1 is composed of two subunits, HIF1  and HIF1 . In normoxia, HIF1  is oxidized
by prolyl hydroxylase. pVHL binds to the oxidized form of HIF1  and directs it into
proteasomes for degradation. In hypoxia conditions, HIF1 is not oxidized and VHL is
unable to bind it. Therefore, HIF1  levels increase in the cell and HIF1  is transported
to the nucleus where it dimerizes with HIF1  and forms an active transcription factor
HIF1. HIF1 evokes the expression of a cohort of target genes encoding, for example,
growth factors involved in angiogenesis such as vascular endothelia growth factor
(VEGF), platelet-derived growth factor (PDGF), and transforming growth factor 
(TGF ). Mutations in VHL lead  to  inactive  forms  of  pVHL,  which  are  unable  to  bind
HIF1  and direct it to degradation. This results in accumulation of HIF1  in the cell
also in normoxia, and continuous expression of HIF1 target genes (Kim and Kaelin
2004).
Hereditary papillary RCC (HPRC, OMIM 605074) is characterized by the development
of multiple, bilateral papillary type 1 renal cell tumours (Zbar et al., 1994, 1995). HPRC
is inherited dominantly and is caused by mutations in the MET oncogene at
chromosome 7q31-q34 (Schmidt et al. 1997). Duplications at the MET locus have also
been observed in tumours (Zhuang et al. 1998). MET encodes a cell-surface tyrosine-
kinase receptor for hepatocyte growth factor (HGF) (Bottaro et al. 1991). Duplications
or mutations in MET lead to constitutive activation of the receptor, aberrant signalling,
enhanced kinase activity, and increases in the invasive and metastatic properties of the
cell (Giordano et al. 1997, Jeffers et al. 1997, 1998, Schmidt et al. 1997).
Birt-Hogg-Dubé syndrome (BHD, OMIM 135150) was characterized for the first time
in 1977 by Birt and colleagues (Birt et al. 1977). BHD is inherited dominantly and is
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characterized by renal tumours, hair follicle hamartomas, and spontaneous
pneumothorax (Nickerson et al. 2002). The histology of renal tumours vary, including
papillary RCC, clear cell carcinomas, and oncocytomas (Toro et al. 1999). BHD
syndrome is caused by mutations in the gene encoding folliculin (FLCN) at
chromosome 17p11 (Nickerson et al 2002). The function of FLCN is unknown.
Tuberous sclerosis complex (TSC, OMIM 191100) is a dominantly inherited syndrome
reported for the first time in 1969 (Anderson and Tannen 1969). TSC is characterized
by the presence of hamartomas in multiple organ systems. Central nervous system
lesions cause epilepsy, learning difficulties, and behavioral problems. Many patients
have renal lesions, usually angiomyolipomas, but renal cysts and RCC have also been
reported  (Crino  et  al.  2006).  TSC  is  a  genetically  heterogeneous  disease  with  two
identified predisposing genes, TSC1 at  chromosome  9q34  and TSC2 at chromosome
16p13 (Consortium TECTS 1993, van Slegtenhorst et al. 1997).
In addition to hereditary syndromes characterized by RCC, familial RCC could be
associated with thyroid carcinoma syndrome hyperparathyroidism-jaw tumour
syndrome (HPT-JT, OMIM 145001). HPT-JT syndrome is characterized by
hyperparathyreoidism caused by parathyroid tumours, and the predisposing gene for this
syndrome is HRPT2 at chromosome 1q25-p32 (Carpten et al. 2002). RCC is also
infrequently observed in patients diagnosed with hereditary non-polyposis colorectal
cancer (HNPCC, OMIM 120435; Lynch and de la Chapelle 1999). The most common
features of HNPCC are colorectal and endometrial cancer, but individuals with this
syndrome also have increased risk of stomach, ovary, ureter, and small bowel cancers
(Mecklin and Järvinen 1991, Lynch and de la Chapelle 1999). While HNPCC is caused
mainly by mutations in DNA mismatch repair (MMR) genes MHS2 and MLH1
(mutations in these genes explain approximately 60% of HNPCC cases), mutations in
other MMR genes, PMS and MSH6, have also been reported (Fishel et al. 1993, Leach
et al 1993, Bronner et al. 1994, Nicolaides et al. 1994, Papadopoulos et al. 1994,
Akiyama et al.1997, Miyaki et al.1997, Worthley et al. 2005). Hereditary RCC is also
infrequently associated with translocations in chromosome 3. A family with clear cell
RCC and a translocation t(3;8)(p14;q24) was reported in 1979 for the first time (Cohen
et al. 1979). The disease was of early onset and dominantly inherited, and the
occurrence of renal tumours was bilateral. The observed translocation produced a fusion
of two genes, FHIT and TRC8 (Ohta et al 1996, Gemmill et al 1998). However, the role
of these genes in the tumourigenesis has remained controversial. Since 1979, several
RCC cases with translocations at chromosome 3 have been reported (Kovacs et al.
1989, Schmidt et al.1995, Bodmer et al. 1998, 2002, Gemmill et al. 1998, Koolen et al.
1998, Kanayama et al. 2001, Melendez et al. 2003, Rodriguez-Perales et al. 2004,
Foster et al. 2007).
1.3 Uterine leiomyosarcoma
Uterine leiomyosarcoma is a rare and highly malignant type of smooth muscle tumour
accounting for only 1-3% of uterine malignancies. ULMSs are diagnosed mainly after
menopause in women over 40 years of age (Barbieri and Andersen 1992). The genetic
background and pathogenesis of ULMSs are poorly understood. ULMSs are typically
characterized by numerous inconsequent chromosomal aberrations including losses of
chromosomes 1p, 10q, 13q, 14q, and 22q, as well as gains of chromosomes 1, 8, 10, 17,
and X (Packenham et al. 1997, Levy et al. 2000, Hu et al. 2001). However, a few
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specific genetic changes have been observed in non-syndromic ULMSs, such as gene
mutations in TP53, PTEN and FH (de Vos et al. 1994, Amant et al. 2002, Kiuru et al.
2002). It has also been presumed that ULMS could be a malign counterpart of benign
uterine  leiomyoma,  and  that  0.1%  of  uterine  leiomyomas  would  progress  to  ULMS
(Barbieri and Andersen 1992, Walker and Stewart 2005, Morton 1998). However, no
chromosomal aberrations common to ULMS and uterine leiomyoma have been
demonstrated in recent cytogenetic studies (Packenham 1997, Levy et al. 2000).
Furthermore, in gene expression studies a number of genes have been observed to be
differentially expressed in ULMS compared to uterine leiomyoma (Skubitz and Skubitz
2003). In addition to the exceptional occurrence of sporadic ULMSs, these tumours are
infrequently observed as a part of the phenotype in some hereditary cancer syndromes.
As mentioned above, HLRCC in one of these hereditary syndromes characterized in
part by early onset ULMS, but it has been observed only in Finnish HLRCC families
(Kiuru and Launonen 2004). The only exception is a family with a patient diagnosed
with ULMS, RCC and leiomyomas reported in 1973 by Reed and colleagues. In Finnish
HLRCC families, ULMS has been diagnosed in 5 families out of 7 (71%) and the ages
of the patients have been exceptionally young, varying from 27 to 39 years (Kiuru and
Launonen 2004). Therefore, the risk of ULMS among FH mutation carriers is 71-fold
when compared to the general population (Lehtonen et al. 2006). An FH mutation has
also been detected in one patient with seemingly sporadic ULMS without a familial
cancer history (Kiuru et al. 2002). However, the patient carried the mutant allele in the
germline, and therefore the tumour was not purely somatic. In addition to ULMS,
several HLRCC patients have been diagnosed with atypical uterine leiomyoma (Toro et
al. 2003, Lehtonen et al. 2006). Atypical leiomyoma is a variant form of leiomyoma,
which might sometimes be difficult to distinguish from leiomyosarcoma.
ULMS have also been observed in Li-Fraumeni syndrome (LFS, OMIM 151623,
609265), which is inherited dominantly and characterized by different early onset
tumours, such as soft tissue sarcomas and osteosarcomas, breast cancer, brain tumours,
leukemia, and adrenocortical carcinoma (Li and Fraumeni 1969, 1982). LFS is caused
by mutations in the TP53 gene at chromosome 17p13 (LFS1, OMIM 151623) or the
CHEK2 gene at chromosome 22q11 (LFS2, OMIM 609265) (Malkin et al. 1990, Bell et
al. 1999).
1.4 Tricarboxylic acid cycle
The tricarboxylic acid cycle (TCAC, citric acid cycle, Krebs cycle) is a central pathway
for  oxidation  of  the  acetyl  groups  of  carbohydrates,  lipids  and  proteins  to  carbon
dioxide and water. The TCAC functions in aerobic conditions in the matrix of the
mitochondria (figure 3). All human cells contain variable numbers of mitochondria, the
double membrane-bounded cell organelle. The majority of the adenosine triphosphate
(ATP), which is the ‘molecular currency’ of intracellular energy transfer, is produced in
mitochondria via the TCAC and oxidative phosphorylation (Alberts et al. 1994). During
each turn of the TCAC, three hydride ions are transferred to three NAD+ molecules, and
one  pair  of  hydrogen  atoms is  transferred  to  an  FAD molecule,  when 3  NADH and 1
FADH2 molecules are formed. These electron carriers transfer electrons to the electron
transport chain (ETC), in which the electron carriers are oxidized yielding nine
molecules of ATP. In the ETC, electrons are transferred from NADH and FADH2 to
CO2 by a series of electron carriers, which is coupled with pumping of H+ into
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mitochondrial intermembrane space. The membrane potential is released through the
fifth complex of respiratory chain, the ATP synthase, and utilized to phosphorylate
ADP + Pi to ATP. ETC takes place in the inner membrane of mitochondria and consists
of complexes I-IV. The respiratory chain consists of complexes I-V (figure 3). (Stryer
1999)
1.4.1 The role of succinate dehydrogenase and fumarate hydratase in TCAC
Succinate dehydrogenase (SDH, ETC complex II)  is  a nuclear-encoded enzyme of the
TCAC which converts succinate to fumarate by oxidation (figure 3). In addition, SDH
functions as a component of the ETC and has some specific redox properties to handle
superoxides which are formed in oxidation-reduction processes (Carrel et al. 1990,
Rustin et al. 2002). SDH is embedded in the inner membrane of mitochondria in
contrast to the other enzymes of the TCAC, which are located in the matrix of the
mitochondria.  Thus,  SDH  forms  a  direct  linkage  between  the  TCAC  and  ETC  of
oxidative phosphorylation (Stryer 1999). SDH is a part of respiratory complex II
(succinate-ubiquinone oxidoreductase) and consists of four different subunits named
SDHA, SDHB, SDHC, and SDHD in order of decreasing molecular weight. Subunit A
is a flavoprotein with a molecular weight of 70 kDa and contains the active site of the
enzyme. Subunit B is a 27 kDa iron-sulfur protein in which the iron-sulfur cluster
functions as an electron carrier (Carrel et al. 1990, Au et al. 1995). Subunits A and B
together comprise the part of the enzyme that projects out from the inner membrane and
is active in the citric acid cycle (Carrel et al. 2002). The whole enzyme complex is
anchored into the inner membrane by integral membrane proteins, SDHC (15 kDa) and
SDHD (12 kDa) (Parfait et al. 2000). SDHC and SDHD are also required for
transferring electrons from SDH to ubiquinone, which is also called coenzyme Q
(Rustin et al. 2002).
As  SDH  oxidizes  succinate  to  fumarate  in  the  TCAC,  one  hydrogen  atom  (H2) is
released. Covalently bounded FAD in the active site of SDHA functions as an acceptor
of the released hydrogen. The reduced form, FADH2, does not dissociate from the
enzyme but two electrons are transferred directly from FADH2 to the iron-sulfur cluster
of SDHB. In the next stage, electrons are transferred from the iron-sulfur cluster to
ubiquinone and further to the ETC (Stryer 1999). The reduced form of ubiquinone also
functions as an antioxidant for biological membranes protecting them from oxidation
(Ernster et al. 1995). Thus, ubiquinones reduced by SDH function as an antioxidant
reservoir in the inner membrane of mitochondria (Rustin et al. 2002).
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Figure 3. Tricarboxylic acid cycle and electron transport chain in mitochondria.
The TCAC occurs in the matrix of the mitochondria. SDH (A, B, C, and D, complex II)
participates in the TCAC and converts succinate to fumarate. FH, in turn, hydrates
fumarate into malate. The other enzymes of TCAC are placed in boxes. SDH
participates also in the ETC in the inner membrane, and forms a direct link between the
TCAC and ETC. Electrons (e-), which are formed in the TCAC, are bound to FADH2,
and transferred from SDHA via SDHB, SDHC, and SDHD through ubiquinone (Q) to
complex III. Hydrogen ions (H+) are pumped into intermembrane space. The membrane
potential is released through the complex V and ATP is formed. Modified from Rustin
et al. (2002).
Fumarase hydratase (FH, fumarase) is a nuclear encoded enzyme which functions in
the  TCAC  immediately  after  SDH,  and  hydrates  fumarate  into  malate  (figure  3).  The
functional enzyme is a homotetramer consisting of four similar subunits with a
molecular  weight  of  50  kDa  each.  In  addition  to  this  mitochondrial  form,  a  cytosolic
form of FH also exists. The known functions of the cytosolic form are fumarate
metabolisms in the amino acid metabolism and urea cycle. Both the mitochondrial and
cytosolic forms of the FH protein are identical (Sass et al. 2003). The exact mechanism
through which this dual targeting is accomplished in human cells is not clear. However,
























































FH are first targeted and processed in the mitochondria. Thus, after the removal of the
mitochondrial signal peptide, cytosolic FH returns to the cytoplasm (Knox et al. 1998,
Sass et al. 2001, 2003).
1.4.2 Paragangliomas and pheochromocytomas result from defective SDH
Defects of SDH are relatively rare in humans, which indicates its indispensability for
the function of mitochondria (Rustin et al. 2002). Inherited mutations in different
subunits of SDH cause different diseases. Heterozygous mutations of three subunits,
SDHB, SDHC, and SDHD, cause tumour predisposing syndromes, while homozygous
mutations in SDHA cause severe neurological symptoms (Rivner et al. 1989, Bourgeron
et al. 1995, Baysal et al. 2000, for a review, see Eng et al. 2003). Mutations in any SDH
subunits result in decreased enzyme activity. In SDH deficiencies caused by mutations
in SDHA, residual activities are quite high in tissues, manifesting 25-50% of control
mean enzyme activities. This suggests that homozygous null mutants are lethal. In
contrast to tissues with homozygous SDHA mutations, tumour tissues with mutations in
both alleles of SDHB, SDHC, or SDHD have measured activities of almost zero
(Bourgeron et al. 1995, Birch-Machin et al. 2000, Parfait et al. 2000). SDHB, SDHC,
and SDHD have been thought to act as tumour suppressor genes and LOH has been
frequently observed in tumours (for a review, see Baysal 2002).
The roles of mutated SDHB, SDHC, and SDHD in neoplasias were identified quite
recently (Baysal et al. 2000, Astuti et al. 2001, Carrel et al. 2002, Niemann and Muller
2000). Mutations in SDHB have been reported to cause classical autosomal inherited
neoplasia syndromes with pheochromocytomas as well as head and neck
paragangliomas (Astuti et al. 2001). Additionally, numerous sporadic PCCs with SDHB
mutations have been reported (Cascon et al. 2002a, van Nederveen et al. 2006).
Mutations in SDHD cause hereditary and sporadic PGL (OMIM 168000) as well as
sporadic PCC (Carrel et al. 2002, Cascon et al. 2002b, Neumann et al. 2002). SDHD
mutations have been reported also in one case of midgut carcinoids (Kytola et al. 2002).
Mutations in SDHC are clearly more infrequent than mutations in SDHB or SDHD,
since  only  four  cases  of  PGL  with SDHC mutations have been reported to date
(Niemann & Muller 2000, Niemann et al. 2003, Bayley et al. 2006, Schiavi et al. 2006).
PCCs are rare and usually benign adrenal medullary tumours, whereas PGLs are extra-
adrenal pheochromocytomas, located in the abdominal and mediastinal sympathetic
ganglions (OMIM 171300). Approximately 10% of PCCs and up to 50% of PGLs are
familial (Astuti et al. 2001). It has been estimated that approximately 50% of familial
PCCs and 20% of familial and 3% of sporadic PGLs are caused by SDHB mutations
(Astuti et al. 2001, Baysal et al. 2002, Cascon et al. 2002a). Baysal et al. (2002) has also
estimated that SDHD mutations might be responsible for approximately 50% of familial
PGLas and 5% of sporadic cases. Interestingly, PGLs caused by mutations in SDHD are
inherited paternally, whereas there is no evidence of parent-of-origin effects for SDHB
and SDHC mutations (Baysal et al. 2000, Niemann et al. 2003).
Mutations in SDHA cause encephalomyopathies with distinct phenotypes (Bourgeron et
al. 1995, Birch-Machin et al. 2000, Parfait et al. 2000, Van Coster et al. 2003, Horvath
et al. 2006). These syndromes include infantile encephalopathies, such as Leigh
syndrome (OMIM 256000), as well as hypertrophic cardiomyopathy, with or without
skeletal muscle myopathy, and late-onset neurodegenerative syndrome with optic
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atrophy, ataxia and myopathy (Leigh 1951, Burgeois et al. 1992, Bourgeron et al. 1995,
Birch-Machin et al. 1996, Reichmann and Angelini 1994).
1.4.3 HLRCC and FH deficiency are consequences of defective FH
Similarly to SDH, mutations in FH cause two different phenotypes: a cancer syndrome
called HLRCC (see section 1.2.1.1) and a childhood encephalopathy called FH
deficiency (FHD, OMIM 606812). HLRCC is characterized by benign and malign
tumours, whereas FHD is characterized by developmental delay, hypotonia,
encephalopathy and fumaric aciduria, and patients typically survive only a few months
(Gellera et al. 1990). HLRCC is caused by heterozygous germline FH mutations,
whereas FHD results from homozygous (or compound heterozygous) mutations
(Tomlinson et al. 2002, Bourgeron et al. 1994, Coughlin et al. 1993). Pathogenic
mutations in FH result in decreased enzyme activity: the activities in homozygous FHD
patient tissues and in HLRCC patient tumours are close to zero, whereas in the normal
tissues  of  HLRCC patients  and  in  heterozygous  parents  of  FHD patients  the  activities
are approximately 50% of the normal values (Gellera et al. 1990, Coughlin et al. 1998,
Alam et al. 2003, Tomlinson et al. 2002, Pithukpakorn et al. 2006).
Both of these syndromes occur rarely. So far, a total of 137 distinct HLRCC families
have been reported worldwide (Launonen et al. 2001, Kiuru et al. 2001, Kiuru et al.
2002, Alam et al. 2003, Martinez-Mir et al. 2003, Toro et al. 2003, Chan et al. 2005,
Chuang et al. 2005, Kim 2005, Badeloe et al. 2006, Chuang et al. 2006, Lehtonen et al.
2006, Lehtonen et al. 2007, Varol et al. 2006, Wei et al. 2006). FHD, in turn, has been
diagnosed in 20 unrelated families (Bourgeron et al. 1994, Gellera et al. 1994, Rustin et
al. 1997, Coughlin et al. 1998, Alam et al. 2003, Remes et al. 2004, Loeffen et al. 2005,
Pollard et al. 2005b, Deschauer et al. 2006, Maradin et al. 2006, Phillips et al. 2006,
Zeng et al. 2006). Altogether, 88 different FH mutations have been reported. Seventy-
one of these mutations have been reported in tumours characteristic of HLRCC, 18 in
FHD patients, and 6 in both of these syndromes (table 1). In addition to tumours
detected in HLRCC families, FH mutations have been reported infrequently in other
tumours (Kiuru et al. 2002, Lehtonen et al. 2004, Carvajal-Carmona et al. 2006). The
mutations observed in both syndromes are spread uniformly along the gene and the
mutation spectrums overlap (table 1). Point mutations in four different codons, R58,
K187, R190, and H275, as well as a three base pi insertion 435insAAA have been
observed in both HLRCC and FHD families (Gellera et al. 1994, Chuang et al. 2005,
Coughlin et al. 1998, Tomlinson et al. 2002, Toro et al. 2003, Pollard et al. 2005b,
Deschauer et al. 2006, Wei et al. 2006). However, the phenotypes of these syndromes
are totally distinct. While the penetrance of leiomyomas among HLRCC patients is
high, being approximately 85-89%, the heterozygous parents or siblings of FHD
patients do not typically display the features of HLRCC (Alam et al. 2003, Remes et al.
2004, Deschauer et al. 2006). Leiomyomas have been observed in only three
heterozygous relatives of FHD patients in two unrelated FHD families out of 20
families examined to date (Tomlinson et al. 2002, Maradin et al. 2006).
Table 1. FH mutations reported to date. Altogether, 88 distinct mutations have been
reported, of which 71 have been observed in tumour types characteristic of HLRCC, 18
in FHD patients, and 6 in both syndromes. In addition, mutations in several other
tumour types have been reported (marked as superscript). No correlations between
phenotypes and type or site of FH mutation were observed.
Skin/uterine
Exon Mutation Leiomyoma RCC ULMS FHD
All Whole gene deletion Tomlinson et al. 2002
Alam et al. 2005a
1 Q4X Tomlinson et al. 2002
Chuang et al. 2005
1 R8E1*
1 1bp del, L17fsX17 Tomlinson et al. 2002
1 1bp ins, K37fsX Wei et al. 2006 Wei et al. 2006
1 2bp del, V41fs* Tomlinson et al. 2002
Intron 1 IVs1+1G>C Wei et al. 2006
2 R58X6 Tomlinson et al. 2002 Wei et al. 2006 Pollard et al. 2005b
Varol et al. 2006
2 R58P Chan et al. 2005 Chan et al. 2005
2 N64T3 Tomlinson et al. 2002
Wei et al. 2006
2 A74P Tomlinson et al. 2002
2 1bp del, N78fsX85 Badeloe et al. 2006 Badeloe et al. 2006
Intron 2 IVS2+1 delG Badeloe et al. 2006
 3 L89S Wei et al. 2006 Wei et al. 2006
3 H92R Chuang et al. 2005
3 1bp del, V97fsX Toro et al. 2003
3 S102X Wei et al. 2006
3 S115I Martinez-Mir et al. 2003
Chuang et al. 2005
3 R117G Wei et al. 2006
3 P131R Alam et al. 2003
Zeng et al. 2006
3 H137R Tomlinson et al. 2002
3 Q142R Tomlinson et al. 2002
3 Chuang et al. 2005
3 Q142X Martinez-Mir et al. 2003
3 Q142K Badeloe et al. 2006
Intron 3 IVS3+1 G>A Badeloe et al. 2006
4 S144L Toro et al. 2003
4 N145S Toro et al. 2003
4 P149L Chuang et al. 2005
4 M152T Toro et al. 2003
4 H153R Kiuru et al. 2001 Kiuru et al. 2002
4 2bp del, E181fsX2052 Kiuru et al. 2002 Tomlinson et al. 2002 Tomlinson et al. 2002
4 I186T Alam et al. 2003
4 3bp del I186 Tomlinson et al. 2002
4 K187R Tomlinson et al. 2002 Coughlin et al. 1998
Toro et al. 2003
Chuang et al. 2005
4 R190L Toro et al. 2003
Chuang et al. 2006 Chuang et al. 2006
4 R190H Tomlinson et al. 2002 Toro et al. 2003 Gellera et al. 1994
Wei et al. 2006 Wei et al. 2006
Chuang et al. 2005
4 R190C Chuang et al. 2005 Wei et al. 2006 Rustin et al. 1997
4 A196T* Lehtonen et al. 2004
intron 4 IVS4+3 A>G* Lehtonen et al. 2004
5 R233H Loeffen et al. 2005
5 G239V Tomlinson et al. 2002
5 L240X* Kiuru et al. 2002
6 2bp del, L260fsX Toro et al. 2003
6 P261fsX Toro et al. 2003
6 A265T Coughlin et al. 1998
6 N267Y Alam et al. 2005a
6 F269C Coughlin et al. 1998
6 H275Y Chuang et al. 2005 Toro et al. 2003 Deschauer et al. 2006
Toro et al. 2003
6 4bp del, 1081del4 Chuang et al. 2005
6 V279D Toro et al. 2003
6 M285R Tomlinson et al. 2002
6 T287P Kim 2005
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6 T287P Chuang et al. 2006
6 L292P Toro et al. 2003
6 N297D Toro et al. 2003
6 N297K Wei et al. 2006
6 R300X Tomlinson et al. 2002 Tomlinson et al. 2002 Tomlinson et al. 2002
6 E312K Alam et al. 2003
6 4bp del, N318fsX Martinez-Mir et al. 2003
6 N318K Alam et al. 2003 Alam et al. 20034
6 E319Q Bourgeron et al. 1994
6 S322G Toro et al. 2003
Wei et al. 2005
6 S323N Alam et al. 2003
intron 6 905G>A, splice Chuang et al. 2005
7 P326S Maradin et al. 2006
7 N330S Lehtonen et al. 20075
7 Q333P Remes et al. 2004
Phillips et al. 2006
7 2bp ins, E335fsX Toro et al. 2003 Toro et al. 2003
7 A342D Wei et al. 2006
7 3bp del, V344del
Q343H
Maradin et al. 2006
7 6bp del, delA350-
V351
Chuang et al. 2005
7 V351L Martinez-Mir et al. 2003
Chuang et al. 2005
7 G354R Alam et al. 2003
7 H360C Phillips et al. 2006
8 S376P Wei et al. 2006 Wei et al. 2006
8 D383V Coughlin et al. 1998
8 1bp del, T388fsX Toro et al. 2003 Toro et al. 2003
8 Q396P Wei et al. 2006 Wei et al. 2006
8 E404X Badeloe et al. 2006
8 1bp del, L406fsX410 Tomlinson et al. 2002
9 M411I3
9 1bp del, I413fsX449 Badeloe et al. 2006
9 Y422C Toro et al. 2003
9 3bp ins, 435insK Gellera et al. 1994
Coughlin et al. 1998
Deschauer et al. 2006
Rustin et al. 1997
9 S437fsX Toro et al. 2003
9 1bp del, G447fsX Toro et al. 2003 Toro et al. 20037
9 W458X Coughlin et al. 1998
9 L464P Alam et al. 2003
9 3bp ins, 477insK Loeffen et al. 2005
1 Soft tissue sarcoma, Kiuru et al. 2002
2 Breast carcinoma, bladder carcinoma, Tomlinson et al. 2002
3 Leydig cell tumour of testis, Carvajal-Carmona et al. 2006
4 Renal collecting duct cancer (CDC)
5 Bilateral, papillary type 2 and conventional RCC
6 Ovarian cysts, Varol et al. 2006
7 Papillary type 2 and collecting duct RCC
* Somatic mutation
1.4.4 Tricarboxylic acid cycle and cancer
It is not completely clear how defects in the TCAC lead to cancer formation. However,
defects in SDH or FH result in decreased enzyme activities and prevent the normal
function of the TCAC leading to the accumulation of succinate and fumarate in cells
(Gellera et al. 1990, Coughlin et al. 1998, Alam et al. 2003, Tomlinson et al. 2002,
Pithukpakorn et al. 2006, Bourgeron et al. 1995, Birch-Machin et al. 2000, Parfait et al.
2000, Selak et al. 2005, Pollard et al. 2005b). Several hypotheses of how this
phenomenon leads to tumourigenesis have been proposed (Eng et al. 2003, Pollard et al.
2003, Gottlieb and Tomlinson 2005). These include, for example, accumulation of
rective oxygen species (ROS) and oxidative stress, aberrant energy metabolism,
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activation of glycolysis, mitochondrial dysfunction and defective apoptosis, activation
of the hypoxia pathway in normoxia (pseudo-hypoxia), and the unknown function of the
cytosolic form of FH (Eng et al. 2003, Pollard et al. 2003, Kiuru and Launonen 2004,
Gottlieb and Tomlinson 2005, King et al. 2006). Currently, the strongest evidence has
been for pseudo-hypoxia, the activation of the HIF-pathway in normoxia (King et al.
2006, Briere et al. 2006). Actually, the overexpression of HIF1 and its target genes have
been observed in both SDH and FH deficient cell lines (Isaacs et al. 2005, Pollard et al.
2005b, Selak et al. 2005). Recently, accumulation of fumarate or succinate in cells due
to defective FH or SDH have been shown to inhibit HIF1 prolyl hydroxylation in
several independent studies (Selak et al. 2005, Pollard et al. 2005b, Koivunen et al.
2006). Therefore, fumarate and succinate seem to function as intracellular messengers
between mitochondria and cytoplasm. The inhibition of prolyl hydroxylases (PHDs)
leads to the stabilization of HIF1 and further to the increased expression of HIF1-
regulated genes such as VEGF. Tumours with SDHB, SDHD and FH mutations have
been reported to be highly vascularized, indicating activation of the HIF1 pathway
(Gimenez-Rogueplo 2001, Pollard et al. 2005a).
2 AIMS OF THE STUDY
This study aimed to define the role of two mitochondrial enzymes, SDH and FH, in
human tumourigenesis. More detailed aims of each study were as follows:
I) To define the role of mutations in SDH genes in early onset renal cell carcinoma.
II) To define the role of FH in early onset uterine leiomyosarcoma.
III) To identify new HLRCC families and further define the spectrum of tumours related
to defective FH function.
IV) To characterize the structure and function of a novel variant form of the FH gene.
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3. MATERIALS AND METHODS
3.1 Patient materials
3.1.1 Renal cell carcinomas (I)
Early onset RCCs (diagnosed between 15 and 34 years of age) of any histological type
were sought from the Finnish Cancer Registry. The Finnish Cancer Registry is the
nationwide and population-based database, which contains information of all cancer
cases diagnosed in Finland since 1953. Therefore, the registry provides a unique
opportunity to collect cancer related data and population based materials. Patients
younger than 15 years of age were omitted due to the abundant occurrence of Wilms
tumour during childhood. In addition, cases diagnosed before the year 1985 were
excluded due to poor quality of DNA and problematic handling of old paraffin-
embedded tissues. The search revealed 244 unrelated patients. The pedigrees were then
expanded through the Finnish Population Registry, and the cancer history of the
families was documented through the Finnish Cancer Registry and patient records.
After these searches, one family with a potential family history (Fam1) was selected for
further analyses. This family included a proband diagnosed with clear cell RCC at the
age of 28 years and his mother diagnosed with malignant paraganglioma (PGL) of the
heart at the age of 55 years. In addition, two maternal uncles of the proband were
diagnosed with small-cell lung cancer and pancreatic carcinoma at the ages 55 and 71
years, respectively. Another family (Fam2) was ascertained through the search for RCC
patients from the Population-based registry of the Freiburg-Warsaw-Columbus
Pheochromocytoma Study Group. Fam2 contained two siblings diagnosed with RCCs
of solid histology at the ages of 24 and 26 years. Both patients had also suffered PGL.
In addition, 95 sporadic RCC tumours of various histologies were selected for mutation
analyses (table 2).  The collection and the documentation of the samples were
performed in accordance with the institutional review boards for human subjects’
protection  of  the  University  of  Helsinki,  the  Ohio  State  University,  the  University  of
Freiburg, and the Institute of Cardiology of Warsaw.
DNA extraction from the paraffin-embedded tumour and normal tissues was carried out
using deparaffinization with xylene, washing with ethanol, treatment with proteinase K,
and extraction with phenol and chloroform (Kannio et al. 1996; studies I-IV).
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Table 2. Histologies of sporadic RCC tumours analysed in study I.
Tumour histology N Population
Clear cell
         of which early onset (under 50 years) 35 American
         diagnosed at any age 30 Finnish
Papillary 3 Finnish
Granular cell 2 Finnish
Mixed papillary / clear cell 1 Finnish
Mixed clear cell / solid histology 1 Finnish
Oncocytic papillary 9 Finnish
Oncocytoma 14 Finnish
Total 95
3.1.2 Uterine leiomyosarcomas (II)
The purpose of study II was to investigate early onset ULMS, and therefore we searched
the Finnish Cancer registry to build a population based material of ULMS. The search
revealed altogether 392 cases diagnosed between the years 1984 and 2003. Most of the
patients were diagnosed at ages above 50 years. A total of 81 cases were diagnosed at
less than 46 years of age fulfilling the adjusted criteria for early onset. The majority of
these cases were diagnosed at ages between 41 and 45 years (45/81, 56%) and 36 and
40 years (26/81, 32%). Only ten patients (10/81, 12%) were diagnosed under 35 years
of age. Tumours originated most often from the uterine corpus (57 cases out of 81,
70%) and showed grade 1 (n=28) or 2 (n=29). The details of the material are presented
in table 3.
A pathologist evaluated the proportion of tumour tissue in paraffin-embedded samples
and only samples displaying at least 50% tumour tissue were accepted for DNA
extraction and further analyses. The appropriate tumour tissue samples were available
from 67 individuals. In addition, 280 samples obtained from the Finnish Red Cross were
used as healthy population controls. The study was approved by the ethics committee of
the Helsinki University Central Hospital and the National Authority for Medicolegal
Affairs.
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41 - 45 45 12 Corpus 57 1 28
36 - 40 26 3 Fundus 2 2 29
31 - 35 5 0 NUD 22 3 8
<30 5 3 Unknown 16
Total 81 18 81 81
NUD, non ultra descriptus, undefined
3.1.3 Patient material to study putative FH mutation related phenotypes (III)
A total of 150 samples were included in this study. DNA of 89 samples was extracted
from blood lymphocytes of patients diagnosed with RCC, skin leiomyomas or ovarian
tumours. These samples were collected from Poland. In addition, 13 Finnish ovarian
mucinous cystadenocarcinoma samples and 48 Danish bladder carcinoma samples were
included. The DNA of ovarian tumours and bladder carcinomas were extracted from
fresh frozen tumour tissues. Details of all samples are shown in table 4. The patient
materials were collected either anonymously or following informed consent and the
study was approved by the Ethics Committee of the Helsinki University Central
Hospital and the National Authority for Medicolegal Affairs.
Table 4. Detailed description of the patient material analysed in study III
Samples N Tissue Population
Tumors in probands
     Papillary renal cell cancer 24 Blood lymphocyte Polish
     Single skin leiomyomas 5 Blood lymphocyte Polish
     Ovarian tumours
          Musinous cystadenoma 33 Blood lymphocyte Polish
          Musinous cystadenocarcinoma 22 Blood lymphocyte Polish
          Serous cystadenoma 5 Blood lymphocyte Polish
89
Tumour samples
     Bladder carcinoma 48 Fresh frosen tumour tissue Danish
     Ovarian carcinoma
          Mucinous cystadenocarcinoma 13 Fresh frosen tumour tissue Finnish
61
Total 150
3.1.4 Patient and cell line material for mutation analyses of FHv (IV)
In study IV, altogether 139 human DNA samples were analysed for FH exon  1b
mutations. The material included human tumour cell lines, non-syndromic HLRCC-
associated tumour samples, HLRCC patients without known second hit mutations and
blood samples from FH mutation negative patients. The material is described in detail
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in table 5. The collection and use of the patient material was approved by the National
authority  for  Medicolegal  Affairs  and  the  Ethics  Committee  of  the  Department  of
Medical Genetics, University of Helsinki.
Table 5. Details of the material used in study IV
Samples N Tissue
Non-syndromic HLRCC associated tumours
     Renal cell carcinoma 43 Tumour
     Uterine leiomyomas 39 Tumour
     Uterine leiomyosarcoma 17 Tumour
99
HLRCC tumours without second hit 9 Tumour
FH mutation negative patients
     Early onset RCC 6 Blood
     RCC or leiomyomatosis 4 Blood
10
Human cell lines
     Renal cell carcinoma 12 Cell line
     Prostate cancer 4 Cell line
     Sarcoma 5 Cell line
21
Total 139
3.1.5 Other materials used in study IV
To determine FHv mRNA expression in different tissues, two human multiple tissue
cDNA  panels  (Human  MTCTM Panel  1  and  Human  Fetal  MTCTM panel, BD
Biosciences Clontech, Palo Alto, CA) were used. All cDNA constructs, which were
used to determine the initiation of transcription, were cloned in both pCi-neo
Mammalian Expression Vector (Promega Corporation, Madison, US) and pEGFP-N3
vector (BD Biosciences Clontech, Mountain View, CA). HEK293 (CRL1573, ATCC),
HTB115 (SK-UT-1B, ATCC) and HeLa (CCL-2, ATCC) cell lines were used in cell
line experiments.
3.2 Analysis methods
3.2.1 Mutation analyses of SDH (I)
The protein coding regions and exon-intron boundaries of SDHA, SDHB, SDHC, and
SDHD were analysed by direct sequencing. The oligonucleotide primers for SDHB,
SDHC and SDHD were  obtained  from the  literature  (Astuti  et  al.,  2001,  Baysal  et  al.,
2000) whereas primers for SDHA were designed by the Primer3 program (Rozen and
Skaletsky 2000).
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PCR amplification of the fragments were performed in 50 l reactions containing 100
ng of genomic DNA, 1 x GeneAmp PCR Buffer (Applied Biosystems, Foster City, CA),
300 M of each dNTP (Finnzymes, Espoo, Finland), 1 M of both primers (Sigma-
Genosys, Cambridge, UK), 2.5 units of AmpliTaq Gold  DNA  polymerase  (AB),  and
1.5mM MgCl2.  PCR  cycling  conditions  were  as  follows:  denaturation  at  95 C for 10
min was followed by 34 cycles of denaturation at 95 C for 45 s, annealing at 56 to 62 C
for 1 min and elongation at 72 C for 1 minute, and final extension at 72 C for 10
minutes.
Next, the PCR products were verified by agarose gel electrophoresis and purified using
the QIAquick spin PCR purification kit (QIAGEN, Valencia, CA). The sequencing
reactions were performed using BigDye 3 termination chemistry (AB) according to the
manufacturer’s instructions. Electrophoresis was performed on an ABI3100 Genetic
Analyzer  (AB).  The  sequence  chromatograms  were  analysed  using  the  Multiple
Alignment General Interface lineage program (MAGI), which was available on the web
page of the UK Human Genome Mapping Project Resource Centre.
3.2.2 Mutation analyses of FH (II, III, IV)
Mutation analyses of exons and flanking intronic sequences were performed mainly by
direct genomic sequencing. The PCR conditions and oligonucleotide primers for FH
exons 1-10 were published earlier by Kiuru and colleagues (2002). Oligonucleotide
primers for exon 1b were designed using the Primer3 program (Rozen and Skaletsky
2000). The primer sequences were 5’-GGC TGT CAG AGA GGG TCC TA-3’ for the
forward and 5’-TAC GGG GGA AAC CAT AGT CA-3’ for the reverse primer.  After
amplification, PCR products were verified by agarose gel electrophoresis and purified
using the ExoSAP-IT PCR purification kit (USB Corporation, Cleveland, Ohio, USA).
The  sequencing  reactions  were  performed  using  the  Big  Dye  Terminator  v.3.1  kit
(Applera Corporation, Norwalk, CT) according to the manufacturer’s instructions.
Electrophoresis was performed using an ABI3730 DNA sequencer (Applera
Corporation) according to the manufacturer’s instructions. The sequence
chromatograms were analysed using either Chromas 2.21 (Technelysium Pty Ltd,
Queensland, Australia) or EditView 1.0.1 software (AB).
FH mutation analyses of 48 bladder carcinoma samples (III) and 280 healthy controls
(II) were performed by DHPLC. Amplification of the 10 FH exons was performed as
described earlier by Lehtonen and colleagues (2003). After amplification, PCR reactions
of two samples were pooled together and denatured at 95 C for three minutes, after
which fragments were reannealed by reducing the temperature 0.5 C per 30 seconds for
45 minutes. The DHPLC heteroduplex analyses were performed using automated HPLC
instrumentation  with  an  Agilent  2G  experimental  dsDNA  2.1  x  75mm  3.5  column
(Agilent Technologies, Palo Alto, CA). Optimal melting temperatures for each fragment
were estimated using an algorithm available at the Stanford DHPLC Melt program web
page. Analytical acetonitrile gradients were composed by mixing Helix Buffer Pak A
for DHPLC and 55-75% Buffer Pak B (Varian Analytical Instruments, Walnut Creek,
CA) at a flow rate of 0.4 ml/minute. Samples displaying aberrant chromatograms were
verified by direct sequencing.
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3.2.3 Analysis of allelic imbalance (AI) (II)
The allelic imbalance at the FH locus at chromosome 1q43 was determined by
analysing microsatellite markers. Three flanking microsatellite markers, D1S304,
AL365184, and AL365366, were used. AL365366 (FH-T) was described earlier by
Lehtonen and colleagues (2004) and primer sequences for AL365184 were 5’-CAT
AAT  TGG  AAG  CCA  CTG  GAG-3’  for  the  forward  and  5’-CAT  CAC  CCA  ACT
CAA  GGT  CA-3’  for  the  reverse  primer.  PCR  products  were  analysed  using  an
ABI3730 DNA sequencer (Applera Corporation) according to the manufacturer’s
instructions and the data were analysed using GeneMapper 3.0 (Applera Corporation).
3.2.4 FH enzyme activity assay (II, IV)
An FH enzyme activity assay (Hatch 1978) was used to determine 1) whether the
observed  amino  acid  change  has  functional  consequences  (II)  and  2)  whether  FHv
functions as an active enzyme (IV). Wild type FH (FHWT) was used as a positive control
and non-transfected cells as a negative control. In addition, a mutated form of FH
(FHH153R), which is known to lack enzyme activity, was used as a negative internal
control of transfected cells (unpublished data). The cDNAs of the wild type FH or FHv
were cloned into pCI-neo Mammalian Expression Vector (Promega Corporation,
Madison, US). The mutation K424R was created in an FHWT/pCI-neo construct by site-
directed mutagenesis (QuickChange® Site-Directed Mutagenesis Kit, Stratagene, La
Jolla,  CA) using primers 5’-CCT CAT ATA GGG TAT GAC AGG GCA GCA AAG
ATT GC-3’ and 5’-GCA ATC TTT GCT GCC CTG TCA TAC CCT ATA TGA GG-3’
to generate the 1432A>G substitution. The constructs were verified by sequencing.
The wild type, variant, or mutated constructs (FHWT/pCI-neo, FHv/pCI-neo,
FHK424R/pCI-neo,  and  FHH153R/pCI-neo) were transfected into HEK293 cells (ATCC,
Manassas, VA) using FuGENE 6 Transfection Reagent according to the manufacturer’s
instructions (Roche Applied Science, Indianapolis, IN). The levels of transfection
efficiencies were confirmed by cotransfection of pEGFPN3 plasmid. Twenty-four hours
after transfection cells were centrifuged into pellets and resuspended in 1 ml of 20 mM
HEPES-KOH buffer, pH 7.5, containing 2 mM dithiothreitol. Suspensions were
sonicated for 2 x 3 seconds on ice, centrifuged at 12,000 rpm for 3 minutes and the
supernatants were collected. Cell lysates were stored at -70 C. FH enzyme activities
were measured as described earlier by Hatch (1978) with minor modifications: reactions
were performed in a total volume of 260 l and chicken liver malic enzyme (Sigma,
Missouri, US) was used. The FH enzyme activity assay measures the amount of NADP
consumed in the fumarate-to-malate reaction per minute per mg of total protein in the
sample.  Total protein levels of the cell lysates were measured using the BCA Protein
Assay Kit (Pierce, Rockford, IL).
3.2.5 In silico analyses (II, IV)
To determine the influence of the observed amino acid substitutions on the protein
structure (II), the SwissProt protein modelling server was used. In addition, the
influence of the observed intronic polymorphism was predicted using the GeneSplicer
Web Interface, Splice Site Prediction at the Berkley Drosophila Genome Project web
page, and NetGene2 server.
35
To analyse the promoter and transcription binding site in FH exon 1b (IV), Genomatix
tools Eldorado, GEMS Launcher, Gene2Promoter, and MatInspector were used. To
investigate the conservation of the sequences, we used the ECR Browser (Ovcharenko
et al., 2004), Ensembl database, and NCBI EST database (Boguski et al., 1993). The
Webgene programme was used to make CpG island predictions. The 5’ end of the FHv
transcript was predicted using the CAGE (Cap-Analysis Gene Expression) database
(Carninci et al., 2005), transcription start site database (Suzuki et al., 2004), or variant
transcript databases (Alternative Splicing Gallery; Leipzig et al. 2004, Alternative
Splicing Database Project; Clark and Thanaraj 2002, Thanaraj et al. 2004, Stamm et al.
2006). For internet addresses, see chapter 8.
3.2.6 Analysis of expression of FHv (IV)
3.2.6.1 Analysis of mRNA expression by quantitative RT-PCR
Quantitative real time RT-PCR was used to determine the mRNA expression of FHv in
human tissues and cell lines. Total RNA from cell lines was extracted and transcribed
into cDNA by M-MLV reverse transcriptase (Promega, Madison, WI). The cDNA from
cell lines and tissue panels was amplified using cDNA specific primers and TaqMan
chemistry  (AB),  and  amplification  was  detected  by  the  GeneAmp  5700 Sequence
Detection System (AB). All reactions were done in triplicates, and two human
housekeeping genes, phosphoglyseratekinase and -actin  (BA),  were  used  as
endogenous control genes.
3.2.6.2 Analyses of expression and localization of FHv in cell lines
To study the expression and localization of FHv, the cDNA of FHv was cloned into
pCI-neo Mammalian Expression Vector (Promega) and pEGFP-N3 vector (BD
Biosciences Clontech). To determine the translation initiation codon of FHv, several
constructs with different putative initiation codons were created in FHv-pCI-neo and
FHv-pEGFP-N3 constructs using the QuickChange® Site-Directed Mutagenesis Kit
(Stratagene). The constructs were verified by sequencing. The detailed structure of the
constructs were described in the original article (IV).
Next, the constructs were transfected into HEK 293 cells using FuGENE6 transfection
reagent (Roche, Applied Science, Indianapolis, IN), and the expression and localization
were determined using a Leica TCS SP1 confocal microscope or an Axioplan upright
epifluorescence microscope. Mitochondria were stained with MitoTracker (MitoTracker
Red CMXRos, Invitrogen, Carlsbad, CA) and cells were fixed with 4%
paraformaldehyde 24 hours after transfection. Nuclei were stained with Hoechst’s
nuclear stain and the endogenous FH was detected using porcine fumarase antibody
(Nordic Immunology, Tilburg, the Netherlands) and FITC-conjugated goat anti-rabbit
IgG.
3.2.6.3 Cell culturing and stress experiments
HEK293 and HeLa cells were cultured in DMEM, whereas HTB115 cells were cultured
in MEM. The culture medium was supplemented with penicillin-streptomycin (100
U/ml and 0.1 mg/ml; Sigma-Aldrich) and with 5% FBS for HEK 293 and 10% FBS for
HeLa and HTB115. The conditions were 37 C, 5% CO2 and 21% O2.
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In stress treatment, cells were exposed to glucose or serum deprivation, hydrogen
peroxide, heat shock, or hypoxia (details have been described in original article IV).
After stress treatment, the total RNA and proteins were extracted. The mRNA
expression levels of FH and FHv were measured with quantitative RT-PCR as
described above (4.2.6.1). The protein levels were detected by Western blot.
3.2.6.4 Western blot analyses
The size and amount of either endogenous FH (stress experiment) or cloned FHWT or
FHv were determined by Western blotting. Total protein was extracted from transfected
or stress treated cells, and 20-30 g of protein was loaded into a 10% Tris-HCL gel. FH




4.1 The role of SDH in early onset renal cell carcinoma (I)
The search for early onset RCCs from the Finnish Cancer Registry revealed 244
unrelated cases. The expansion and documentation of pedigrees yielded 19 families with
possible cancer backgrounds, of which one family with the most interesting family
history was selected for further analyses (Fam1; Figure 4a). Fam1 included a 28-year-
old index patient diagnosed with RCC. The histology of the tumour was clear cell
carcinoma, showing a mixture of clear cells and cells with granular-eosinophilic
cytoplasm. At the time of diagnosis, the tumour had already widely metastasized. The
mother of the patient was diagnosed with PGL of the heart at the age of 55 years. The
tumour was considered inoperable and therefore led to the death of the patient. In
addition, two maternal uncles of the index patient were diagnosed with cancer, one with
small-cell lung carcinoma at the age of 55 years and the other with pancreatic carcinoma
at the age of 71 years.
Figure 4. Pedigrees of the RCC families. The  pedigree  structures  of  Fam 1  (A)  and
Fam 2 (B) are presented. The probands of both families are indicated by arrows.
To determine whether FH mutations and HLRCC might explain the formation of these
tumours, the FH gene was analysed by direct sequencing but no mutations were
identified. Existence of the PGL of the heart in the family led to another hypothesis, as
mutations in the FH preceding enzyme, SDH, have been reported in PGLs. To clarify
whether SDH mutations could be the predisposing agent, all four genes encoding the
subunits of SDH (SDHA, SDHB, SDHC, and SDHD) were analysed by sequencing. A
truncating germline mutation R27X (129C>T) was identified in the SDHB gene. The
index  patient,  his  mother,  and  the  uncle  with  lung  carcinoma  were  all  carriers  of  the
mutated allele. LOH was observed in tumours of both the index patient and his mother,
but  not  in  the  lung  cancer  of  the  uncle.  DNA  was  not  available  from  the  other  uncle
with pancreatic carcinoma.
The other family included two siblings diagnosed with RCC of solid histology at the
ages 24 and 26 years, and both patients had also suffered PGL (Fam2; figure 4b).
Genomic DNA of the patients was analysed by direct sequencing and a germline
frameshift deletion c.847-850delTCTC in SDHB was found in both patients. The loss of
the wild type allele was observed in both RCC tumours and in the PGL of one patient.
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Finally, SDHA, SDHB, SDHC, and SDHD were analysed in 95 sporadic RCCs to
determine the frequency of SDH mutations in sporadic RCC cases, but no mutations
were detected.
4.2 The role of FH mutations  in  tumourigenesis  of  early  onset  uterine
leiomyosarcoma (II)
A total of 81 patients fulfilling the adjusted criteria for age were identified from the
Finnish Cancer Registry. Paraffin embedded tumour tissues were available from 67
individuals. Altogether 52 out of 62 tumour-normal pairs available were informative for
one or more microsatellite markers used to determine the AI at the FH locus. Nine
tumours (17%) showed AI at the FH locus. In FH mutation analyses, a novel K424R
(1342A>G) missense change was detected in one tumour. In addition, two silent
polymorphisms were detected. One was in the coding region of exon 6 (927G>A) and
the other in the coding region of exon 8 (1299C>T). Furthermore, 5 silent
polymorphisms were observed in the flanking intronic sequences, but none of those
were predicted to affect splicing in silico.
The patient with the K424R variant was diagnosed at the age of 41 years with a grade 2
ULMS of the uterine corpus. The disease had metastasized 10 years after diagnosis and
the patient died 12 years after the original diagnosis. The patient had no other tumours
and no tumours were reported in her first-degree relatives. The K424R variant was also
found  in  the  patient’s  normal  tissue  and  no  LOH  or  second  hit  were  observed  in  the
tumour tissue. The variant has not been published in dbSNP database. In addition, 280
healthy Finnish population controls were analysed for the K424R mutation by DHPLC
to exclude the possibility of polymorphism but the change was not observed in the
controls. Comparison of the protein sequence with other species showed that the amino
acid K424 is highly conserved across higher species and E.coli, but C.elegans and
S.cerevisiae do not share the lysine at the respective codon (Figure 5).
Figure 5. Sequence alignment of codons 377-436 of FH across species. C.elegans
and S.cerevisiae do not share lysine at codon 424, which exists in higher species,
human, M. musculus, R. norvegicus, and D. melanogaster.
The influence of the variant to the protein structure was predicted in silico, but no
significant changes were observed. To determine the influence of the change to the
function of the protein, an FH enzyme activity assay was performed in cell line model.
The enzyme activity in FHK424R transfected cells was 168 nmol/min/mg of protein,
whereas in FHWT transfected cells it was 390 nmol/min/mg of protein (Figure 6).
Nontransfected cells and cells transfected with mutated FH (FHH153R) with no enzyme
activity (unpublished data) were used as controls. The activities in nontransfected cells
and in FHH153R transfected cells were 36 and 37 nmol/min/mg of protein, respectively.
The levels of transfection efficiency were similar being 34% for FHWT,  38%  for
K424
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FHH153R,  and  42%  for  FHK424R. Thus, the enzyme activity of FHK424R was clearly
reduced, being 43% of the wild type activity.
Figure 6. FH enzyme activity assay in a cell line model. The  enzyme  activity  of
FHK424R was clearly reduced, being 43% of the activity of the wild type protein, FHWT.
Non-transfected cells and cells transfected with FHH153R, which has no enzyme activity,
were used as controls.
4.3 Specification of the spectrum of tumours associated with defective FH (III)
Altogether 150 samples from patients diagnosed with (1) RCC, skin leiomyoma,
ovarian tumour, or (2) bladder carcinoma were analysed for FH mutations. First, blood
samples of patients diagnosed with RCC, single skin leiomyoma or benign ovarian
tumours were analysed in attempts to identify new germline mutation carrying HLRCC
families. The analyses revealed two different FH variants in two patients, both
diagnosed with ovarian mucinous cystadenoma (2/33, 6%). The first was a novel
missense change A231T (691G>A), and the second a three base pair insertion
(435insAAA). The patient with the A231T change was diagnosed with mucinous
cystadenoma of the left ovary and with cysta endometrialis of the right ovary at the age
of 25 years. She has no features or family background of HLRCC. Two second-degree
relatives of the patient had been diagnosed with cancer, one with breast cancer and the
other with leukemia. No tumour DNA from the patient was available for LOH studies.
The 435insAAA insertion was observed in the DNA of the patient diagnosed with the
mucinous cystadenoma of the ovary at the age of 49 years. She was also diagnosed with
small  multiple  uterine  myomas,  but  no  other  HLRCC  features  were  observed.  The
father  of  this  patient  was  also  a  carrier  of  the  same  alteration,  but  without  a  HLRCC
phenotype. The mother of the patient carried normal FH. However, the mother and one
first-degree relative of the patient were also diagnosed with ovarian tumours. No other
familial background of cancer was observed in this family.
Because two germline variants observed in patients with mucinous cystadenoma are
possibly connected to disease predisposition, an additional set of 13 mucinous
cystadenocarcinomas were analysed to determine whether FH mutations also play a role
in these malignant tumours. However, no mutations were detected.
Finally, 48 bladder carcinoma samples were included in the study. Bladder carcinomas
had recently been diagnosed in some of the HLRCC families and this tumour type had
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not been analysed for FH mutations earlier. However, no FH mutations were observed
in the studied bladder carcinomas.
4.4 Characterization of FHv (IV)
A putative alternative form of FH was first identified from the AceView gene database.
A 414 bp sequence (GenBank accession AI971779.1) containing exon 2, a part of exon
3, and an upstream sequence (exon 1b) was derived from ovarian tissue. The first exon
of the mitochondrial FH encodes  a  mitochondrial  signal  peptide.  The  variant  form  of
FH, FHv, contains an alternative first exon 1b which mapped to the intron between
exons 1 and 2. The following exons (2-10) are equivalent in both forms (Figure 7). The
exon 1b sequence was predicted in silico to contain no CpG islands, core promoter,
conserved transcription factor binding sites, nuclear localization signals or hypoxia
response elements. No evidence for the 5’ extension of exon 1b was found in in silico
studies, and the variant exon was not found in other species including M. musculus, R.
norvegicus, B. Taurus, C. familia, P. troglodytes and M. mulatta.
Figure 7. Structure of the FH gene. The organization of the exons and introns of both
forms of FH (FH and FHv), and the structures of transcribed mRNAs and translated
proteins are shown. According to our results, the translation of FHv is in vitro initiated
from three alternative ATGs located in exons 2 and 3. Therefore, 3 protein products of
different sizes are formed (A, B and C).
The mRNA expression of the variant FHv was  measured  by  quantitative  RT-PCR  in
human fetal and adult tissues and in cancer cell lines. The analyses revealed that FHv is
expressed at low levels in all tissues. The expression of mitochondrial FH was
approximately 200 fold greater in fetal tissues and 400 fold greater in adult tissues when
compared to FHv. The FHv expression was highest in embryonic brain and in adult
pancreas.
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The expression of FHv mRNA was analysed by RT-PCR also in cell lines which were
exposed to different stress conditions. Glucose or serum deprivation, H2O2 treatment or
hypoxia (1% O2) did not reveal any prominent changes in mRNA expression levels.
However, the exposure of human uterine leiomyosarcoma cell line (HTB-115) to heat
shock resulted in an increase in FHv mRNA expression levels: heat shock treatment for
30 minutes yielded a 3-fold increase in the expression levels, for 60 minutes 6-fold, and
for 2 hours 9-fold increases, when compared to untreated cells (Figure 8a). A similar
trend was also observed in HEK293 and HeLa cell lines (data not shown). Furthermore,
in prolonged hypoxia (1% O2, 72-96h), a tendency of increased FHv expression was
observed. In hypoxia treated HTB-115 cells, the mRNA expression of FHv was
increased 4-fold when compared to the untreated cells (Figure 8b). The same effect was
also seen in HeLa and HEK293 cell lines. No increase in the expression of FH was
detected under either condition (Figure 8). To confirm this finding, 12 additional cell
lines were subsequently analysed. A trend of stress related induction was also detected
in the half of these cell lines (6 out of 12; data not shown).
Figure 8. Relative mRNA expression levels of FH and FHv after heat shock and in
hypoxia. A)  The  expression  of FHv was increased 9-fold after heat shock treatment
when compared to control cells. No increase was seen in the expression level of
mitochondrial FH (FH). B) In prolonged hypoxia, the expression of FHv was increased
4-fold when compared to untreated cells. Again, no changes were seen in the expression
levels of FH. Relative expression levels are calculated by comparing the expression
levels  of  FH  and  FHv to their own expression in normal conditions and not to each
other. Expression levels of untreated control cells were set to 1.0.
Variant  exon  1b  contains  no  ATG  to  act  as  an  initiation  codon.  Instead,  exon  1b
contains two CTG codons which could function as possible initiation codons. In
addition, there are three in-frame ATG codons in exons 2 and 3. The initiation of the
translation of FHv was determined by transfecting HEK293 cells with FHv-GFP
constructs containing different putative initiation codons. The putative initiation of
translation in different constructs and the size of the translated protein was analysed by
Western blotting. The Western blot analyses of the transfected HEK293 cells yielded
three protein products (46 kDa, 45 kDa and 42 kDa), of which the middle one was very
faint. The possible initiation of translation from either CTG was excluded by mutating
the  CTG  to  CCC,  where  all  three  bands  remained  in  Western  blots.  When  the  CTGs






























those  three  bands.  The  same  method  of  mutating  ATGs  to  CCCs  was  used  to  further
determine the correct initiation codon of the three ATGs in exons 2 and 3: when the first
one was mutated to CCC, the largest band disappeared from the Western blot. Similarly,
when the middle or the last ATG were mutated into CCC, the corresponding band
vanished in Western blot analyses. Thus, translation was initiated from all three ATGs
in exons 2 and 3, while the strongest expression occurred from the first and the last
ATGs. Therefore, these results suggest that exon 1b is a 5’ untranslated sequence of
FHv.
The subcellular localization of the translated protein was determined using confocal
immunofluorescence microscopy. Localization of the overexpressed FHv protein in
transfected HEK293 cells was both nuclear and cytosolic, whereas the FH protein
lacking both exon 1 or 1b was localized in cytoplasm. The endogenous FH or FH-GFP
constructs were localized in mitochondria, while cytosolic fluorescence was also
observed in a subset of FH-GFP overexpressing cells.
FHv was  determined  to  have  no  typical  FH enzyme activity.  The  activity  in  HEK293
cells transfected with FHv was 36 nmol/min/mg of protein, whereas in cells which were
transfected with FH or mutant FH with no activity (FHH153R, unpublished data), or were
not transfected at all, the activities were 390, 35, and 36 nmol/min/mg of protein,
respectively. Transfection followed by overexpression of FH caused a 10-fold increase
in enzyme activity when compared to nontransfected cells. The activity in FHv or
FHH153R transfected cells and nontransfected cells were equal, indicating only the
activity of endogenous FH.
In addition, the mutation status of FHv was determined in 118 patient samples and in 21
cell lines. However, this yielded no mutations in the exon 1b or its flanking sequences.
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5. DISCUSSION
5.1 Mutations in the SDHB gene predispose to RCC (study I)
Early onset RCC has frequently been observed in Finnish HLRCC families (Kiuru and
Launonen 2004). Therefore, we hypothesized that Finnish early onset RCC cases might
include patients carrying FH mutations, and that examination of the familial cancer
history could provide new HLRCC families. One family (Fam1) with a 28-year-old
index patient was revealed from the Finnish Cancer Registry. FH mutation analysis of
the index patient revealed no mutations, and therefore all four subunits of SDH (SDHA,
SDHB, SDHC, and SDHD) were analysed. Although no mutations in SDH subunits had
earlier been reported in RCC, SDH appeared to be a prospective candidate gene for
several reasons. The mother of the index patient had been diagnosed with PGL and
mutations in SDHB, SDHC, and SDHD have recently been reported in PGLs (Niemann
and Muller 2000, Astuti et al. 2001, Carrel et al. 2002). A novel germline mutation,
R27X, was identified in the SDHB gene. The index patient with RCC, his mother with
PGL, and an uncle with lung cancer were carriers of this mutation. LOH was observed
in both the RCC of the index patient and the PGL of his mother. No LOH was observed
in the lung cancer of the uncle, and it is probable that the tumour had developed due to
smoking over 40 years.
This is the first study in which SDHB mutations have been observed to predispose to
RCC. However, even though LOH was observed in the tumour tissue, it can be argued
that the occurrence of RCC in this patient carrying an SDHB mutation  might  be  a
coincidence and that this does not belong to the SDHB-paraganglioma syndrome. This
suspicion was disproven by identification of another family (Fam2) with two siblings
diagnosed with both early onset RCC (at the ages of 24 and 26 years) and PGL. Both
patients carried a germline four bp deletion c.847-850delTCTC in the SDHB gene.
Moreover,  the  RCC of  both  patients  and  the  PGL of  one  patient  showed LOH.  These
observations in two unrelated families confirmed that the existence of early onset RCC
in these families is really caused by the observed SDHB mutations, and this phenotype
did not occur by chance. Therefore, SDHB is a novel susceptibility gene for early onset
RCC. However, RCC seems to be rare even among SDHB mutation positive families. In
the PGL registry, only two RCC cases have been observed in one family among 16
SDHB mutation positive families including 31 mutation carriers. This led to a rough
estimate that the approximate prevalence of RCC would be 5-10% among SDHB
mutation carriers. However, patients included in the PGL registry are mainly young,
with a mean age of 30 years (40%  20 years, 15%  40  years).  Therefore,  the  true
prevalence among SDHB mutation carriers can be somewhat higher, which should be
taken into consideration in the clinical follow-up of patients with PGL and germline
SDHB mutation. No mutations were observed in sporadic RCC cases and it appears that
somatic SDHB mutations have a minor role in RCC.
Since 2001, numerous SDHB mutations have been reported in familial PGLs and PCCs,
as well as in sporadic PCCs. However, no purely somatic mutations have been reported
(van Nederveen et al. 2006). All types of mutations are reported in the SDHB gene and
the mutations occur throughout the gene. No genotype-phenotype correlation has been
observed (van Nederveen et al. 2006, Timmers et al. 2007). Interestingly, it has been
assumed that SDHB mutations might be related to the malignant behaviour of tumours
and that they generate a more aggressive type of PGL disease (Pawlu et al. 2005, van
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Nederveen et al. 2006). Timmers et al. (2007) summarized that malignant disease has
been observed in 55% of the cases, while the rates of malignancy varied between 34 and
97% in different studies.
Germline mutations in genes encoding two consecutive enzymes of the TCAC, FH and
SDH, cause two different cancer syndromes with overlapping features. The early onset
RCC seems to form a link between these two syndromes. Even though the histologies of
renal tumours are different in these syndromes (mostly papillary type 2 in HLRCC and
clear cell or solid histology in SDHB associated tumours), all these carcinomas originate
from epithelial cells of the proximal renal tubule. Tumours of both syndromes seem to
occur at unusually young ages, be unilateral, and especially aggressive. Both SDHB and
FH seem to function as tumour suppressor genes and no mutations in either gene were
detected in sporadic RCC. The consistency of these features indicates that at least some
of the molecular mechanisms of kidney tumourigenesis associated with defective TCAC
enzymes could be similar. Several hypotheses concerning these mechanisms have been
proposed including e.g. mitochondrial dysfunction and apoptosis, ROS and oxidative
stress, pseudo-hypoxia, inaccurate energy metabolism, activation of glycolysis, and
unknown function of SDH or FH. Currently, the pseudo-hypoxia theory seems to be the
one favoured by most researchers (for review see Eng et al. 2003 and King et al. 2006).
Pseudo-hypoxia is also found in the background of the most common hereditary RCC
syndrome, VHL (Latif et al. 1993). In addition to RCC, PGL also occurs in VHL
patients. Mutations in VHL lead to stabilization of HIF1 and activation of hypoxia,
glycolysis, and angiogenic pathways (Kim and Kaelin 2004). Therefore, it seems
probable that a common factor underlying the tumourigenesis of RCC in all these
syndromes could be the activation of the HIF1 pathway. However, this does not explain
the occurrence of different tumour types (leiomyomas in HLRCC and PGGs/PCCs in
patients with SDH or VHL mutations) in cancer syndromes caused by these genes. In
addition, it appears probable that the tumourigenic effect of defective SDH or FH
involves more than one mechanism (King et al. 2006). However, these mechanisms are
probably not identical, since the majority of the features of these syndromes are
different. The unifying tumour type, RCC, seems also to be relatively rare even among
families with these syndromes, and the risk for RCC varies between families. Therefore,
it has been proposed that a modifying factor together with a TCAC defect might be
needed for the development of RCC (for a review see Eng et al. 2003). However, this
modifying factor (or factors) as well as the molecular mechanisms behind TCAC
associated tumourigenesis remain to be identified.
5.2 FH mutations predispose to ULMS and possibly also to ovarian tumours (studies
II and III)
FH was determined to be a cancer predisposing gene quite recently. In studies II and III,
we therefore attempted to clarify the spectrum of FH mutation associated tumours in
more detail. Uterine leiomyosarcoma (ULMS) has been observed in Finnish HLRCC
families and we hypothesized that FH mutations could play a role in the tumourigenesis
of sporadic ULMS. HLRCC patients are diagnosed with ULMS at exceptionally young
ages, varying from 27 to 39 years (Kiuru and Launonen, 2004), and therefore the
criteria of early onset used in the Cancer Registry search was adjusted to  45 years (II).
FH mutation analysis revealed a putative novel germline missense mutation, K424R, in
one patient diagnosed with a grade II tumour of the uterus corpus at the age of 41 years.
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The variant was not reported in SNP databases and was not observed in 280 healthy
population controls. In addition, we have analyzed several hundreds of Finnish samples
for FH mutations in other studies and have never observed the K424R variant in those
studies either. Therefore, it seems unlikely that the variant would be a common
polymorphism. The amino acid K424 is strongly conserved across higher species but in
silico protein prediction suddested no major changes to protein structure. The activity of
FHK424R was clearly reduced, being approximately 43% of the activity of wild type FH.
However, FHK424R still had some activity when compared to negative controls, but the
reduced activity might not be enough for the normal function of the TCAC. These
observations suggest that the variant could be a pathogenic mutation, although it is
impossible to verify since no loss of the wild type allele was detected in tumour tissue
and no segregation data was available from the family. In fact, several patients with
HLRCC phenotypes and reduced FH enzyme activities but no detectable FH mutations
have also been reported in earlier studies (Tomlinson et al. 2002, Alam et al. 2003,
Pithukpakorn et al. 2006). Additionally, FH missense mutations have been observed to
result in lower enzyme activities than truncating mutations, which is probably due to a
dominant-negative effect: the FH protein functions as a homotetramer and a missense
mutation in one allele results in only 1 out of 16 wild-type homotetramers (Tomlinson
et al. 2002). It is also possible that the wild type allele has been silenced e.g. by
hypermethylation at the promoter region, but it seems that the epigenetic inactivation of
FH by hypermethylation at the promoter region is not common in leiomyosarcomas
(Barker et al. 2006). Taken together, it appears that FH mutations may play a role in the
pathogenesis of ULMS of young age at the population level. The frequency of FH
mutations observed in these tumours is lower than expected based on the results from an
earlier study in which Kiuru et al. (2002) detected one FH mutation in one ULMS out of
18 seemingly sporadic unselected cases (1/18, 5.6%). In the present study, one
nonsyndromic ULMS with an FH mutation was detected in the population-based
material (1/67, 1.5%). However, in both cases the mutation has been proven to be
germline. These two studies suggest an estimate that the occurrence of FH mutations in
Finnish non-syndromic ULMS is 2/85 (2.4%).
Uterine leiomyomas and ovarian cystadenomas without BRCA1 mutations have recently
been reported in Polish families with hereditary ovarian cancer (Menkiszak et al. 2004),
and therefore ovarian cystadenomas were included in study III. Two different germline
FH variants were found in two patients diagnosed with ovarian mucinous cystadenoma.
The 25-year-old patient carrying the A231T missense change had no features of
HLRCC and no familial background of HLRCC was observed. The lack of HLRCC
phenotype might be due to the young age of the patient. The mean age at diagnosis of
uterine leiomyomas in HLRCC patients is 31 years, and the relative risk at the age of 25
years has been estimated to be 9% (Alam et al. 2005c). The risk for skin leiomyoma at
the age of 25 years is approximately 28% (Alam et al. 2005c). The 49-year-old patient
carrying the 435AAA three bp insertion had been diagnosed with multiple small uterine
myomas  in  addition  to  mucinous  cystadenoma.  No  other  features  of  HLRCC  were
observed in the patient or in her father, who was also a mutation carrier. This one amino
acid in-frame insertion has been observed earlier in five FH deficiency families and no
HLRCC features were reported either in homozygous patients or in heterozygous
parents or siblings in these families (Gellera et al. 1994, Rustin et al. 1997, Coughlin et
al. 1998, Loeffen et al. 2005, Deschauer et al. 2006). However, the insertion has never
been detected as homozygous but always with a missense mutation in the other allele. In
addition, no data concerning the function of the variant protein has been published.
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Therefore, it is unclear whether this insertion predisposes to ovarian tumours. The FH
mutation negative mother and one first-degree relative of the index patient were
diagnosed with ovarian cancer and the predisposition for ovarian cancer can also be due
to other, maternally inherited factors. Therefore, especially when no tumour tissue were
available from either of these tumours and the LOH status remained unknown, it is
impossible to conclude whether these variants are pathogenic mutations. Ovarian
tumours have not been detected in HLRCC families and no FH mutations have been
found from ovarian tumours in the earlier studies (Lehtonen et al. 2004, Lehtonen et al.
2006). Recently, several other benign tumour types, including atypical uterine
leiomyomas, kidney cysts and adrenal gland adenomas, have been observed in FH
mutation  carriers  (Lehtonen  et  al.  2006).  Therefore,  it  appears  possible  that FH
mutations might predispose to ovarian tumours, but more investigations are needed to
verify these results.
Altogether, 142 sporadic tumours were analysed for FH mutations in studies II and III,
and no tumours with purely somatic mutations were found. According to our results as
well as results from earlier studies, it seems that somatic FH mutations are rarely
enough for tumourigenesis. Thus far, numerous sporadic tumour types, including e.g.
leiomyomas of uterus or skin, RCC, different sarcomas, breast and prostate carcinomas,
and colorectal cancer, have been analysed for FH mutations (Lehtonen 2006). Lehtonen
(2006) found purely somatic mutations in only three tumours (one in a soft tissue
sarcoma and two others in uterine leiomyomas) out of 943 sporadic tumours analysed
for FH mutations. Biallelic inactivation has been detected in almost all HLRCC tumours
as well as in a few sporadic tumours with FH mutations (Lehtonen 2006).
5.3 Identification and characterization of a novel variant form of FH (study IV)
Localization and function of proteins are commonly regulated by removing interaction
or  localization  domains.  This  can  be  done  either  by  using  alternative  start  sites  for
transcription or translation, or by alternative splicing (Mueller et al. 2004, Lareau et al.
2004). Recently, Schwerk and Schulze-Osthoff (2005) have also speculated that
alternative splicing would have an important role in the regulation of apoptosis. A large
number of apoptotic factors are regulated by alternative splicing and defects in those
factors are also detected in cancer. It also seems plausible that alternative splicing is a
mean to regulate intra-cellular messaging. Baek and Green (2005) have analysed a large
set of human gene variants produced by alternative splicing and suggested that the key
roles  of  splice  variants  are  to  regulate  gene  expression  and  mediate  the  destruction  of
intra-cellular messages. However, the large number of splice variants revealed to date
also includes variants produced by aberrant splicing and it is challenging to distinguish
these aberrantly spliced variants from functionally important ones (Baek and Green
2005).
Evidence of a putative novel variant form of FH mRNA was first published in the
AceView gene database. Because FH is a novel cancer gene and its role in
tumourigenesis was unclear, it was reasonable to study and characterize FHv in  more
detail. FHv mRNA was determined to contain an alternative first exon 1b, which,
according to our studies, seems to be an untranslated 5’ sequence. Two alternative
forms of FH (FH and FHv)  might  be  generated  by  different  promoters,  as  described
earlier for several genes with alternative first exons (Ayoubi and van de Ven, 1996;
Hughes, 2006). FHv mRNA is expressed in all human fetal and adult tissues at low
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levels. Interestingly, the expression levels of FHv increased significantly after heat
shock treatment and in prolonged hypoxia. The induction was clearest in the HTB115
cell line but the same effect was also seen in approximately half of the other cell lines
studied (8 out of 14; data not shown). Stress-induced expression of splice variants has
also earlier been reported for several other genes such as VEGF and COX1 (Turpin et al.
1999, Nurmi et al. 2005, Fay et al. 2006). Unfavorable growth conditions are known to
result in heat shock response, in which heat shock factors induce the transcription and
synthesis of heat shock proteins (HSPs), as well as several other proteins (Pirkkala et al.
2001, Sonna et al. 2002, Murray et al. 2004). HSPs are involved in the folding of
proteins, regulation of the redox state, and in protein turnover. Under stress conditions,
HSPs either promote the survival of the cell or induce apoptosis (Sonna et al. 2002).
The increase in the expression level of FHv in unfavorable growth conditions might
suggest that it plays a role in the adaptation of a cell to a disadvantageous environment
or in stress related apoptosis. FHv could also be involved in the processing of
cytoplasmic fumarate or in the shifting of energy metabolism from oxidative
phosphorylation toward the glycolytic pathway. However, these hypotheses remain to
be clarified.
FH enzyme activity was measured from both mitochondrial and whole cell extracts but
no activity was observed. According to our results, translation of FHv is  initiated from
three ATGs located in exons two and three. This results in proteins in which the 5’ end
is 32, 43 or 77 amino acids shorter (initiated from the first, second or third ATG,
respectively) than in the mature mitochondrial FH protein. This might have an effect on
the  formation  of  the  homotetramer  or  on  the  catalytic  activity  of  the  protein  and
therefore result in the lack of enzyme activity. The significance of the absence of FH
enzyme activity is unclear. If the function of FHv is unrelated to fumarate metabolism,
the question of absent enzyme activity is irrelevant. It is also possible that FHv is
produced by aberrant splicing and that it has no biological significance. Both of these
hypotheses are possible and more studies are needed to disprove either of these
alternatives.
FHv contains  no  mitochondrial  signal  peptide  and  localization  of  the  FHv-GFP fusion
protein was both nuclear and cytosolic in vitro, although no nuclear localization signals
had been predicted with in silico analyses. Endogenous FH and FH-GFP protein
localized in mitochondria, while a subset of FH-GFP overexpressing cells displayed
also cytosolic expression. In yeast, the dual localization of FH has been described
earlier and it appears that approximately 70% of fumarase is localized in cytoplasm
(Sass et al. 2001, 2003). In mammalian tissues FH localized primarily in mitochondria
but suggestive evidence of extra-mitochondrial localization of FH has been presented
(Bowes et al. 2006). In addition, extra-mitochondrial localization has also been reported
in several other primarily mitochondrial proteins (Mueller et al. 2004, Bowes et al.
2006). That FHv localization is not mitochondrial and that it seems to have no enzyme
activity suggest that FHv might have some yet unknown function in the cell.
Taken together, we characterized a novel variant form of FH in more detail in this
study. However, the role and the physiological significance of FHv remain unclear. The
FH gene is highly conserved across species, but the counterpart of the variant exon 1b
was not found in other species. FHv has no enzyme activity and although it is expressed
in all human tissues, the expression levels are much lower when compared to the
mitochondrial form of FH. FHv can be translated in vitro and it is not degraded
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immediately, but endogenous expression of FHv has  not  been  detected  reliably  at  the
protein level. Therefore, according to our results, it is evident that FHv mRNA  is
expressed in human tissues and the expression is induced in stress conditions, but the
physiological function and significance of FHv remain to be verified.
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6. CONCLUSIONS
HLRCC was characterized in 2001 for the first time and the predisposing gene, FH, was
identified in 2002. In addition, mutations in another TCAC enzyme encoding gene,
SDHB, were reported in PGLs for the first time in 2001. Because FH and SDH were
novel cancer predisposing genes with well known but seemingly unrelated functions in
the energy metabolism of cells, virtually nothing was known about their roles in
tumourigenesis. Since 2001, increasing amounts of information concerning these genes
and syndromes has accumulated, but there are still numerous open questions. This study
aimed to answer some of these questions by defining the role of FH and SDH mutations
in several tumour types and by characterizing a novel variant form of the FH gene.
I) The  role  of FH and SDH mutations in RCC were studied. Two novel SDHB
mutations  were  detected  in  three  RCC  patients  in  two  unrelated  families.  PGLs
were also diagnosed in both families. This was the first study in which RCC was
reported to be associated with SDHB-paraganglioma syndrome. However, RCC
seems to be rare even among SDHB mutation carriers and no mutations were
detected in sporadic RCC cases. Therefore, more studies are needed to confirm
the prevalence of RCC in this syndrome.
II) The role of FH mutations were studied in population based material of early onset
uterine leiomyosarcomas. One patient with a putative novel germline FH
mutation (1/67, 1.5%) was detected in this study. The patient has no familial
history of cancer and no LOH was observed in the tumour. However, the enzyme
activity of the mutated protein was clearly reduced. Therefore, it seems that FH
mutations play a minor role also in non-syndromic ULMS. One FH mutation has
been detected in non-syndromic ULMS in an earlier study (Kiuru et al. 2002).
Together these results suggest, as a rough estimate, that the prevalence of FH
mutations in Finnish non-syndromic ULMS is 2/85 (2.4%).
III) This study aimed to identify new HLRCC families and define the spectrum of FH
mutation associated tumours. Two different FH variants were detected in a novel
tumour type, ovarian mucinous cystadenoma. Both variants were germline
changes,  but  the  patients  had  no  familial  history  of  HLRCC.  In  addition,  no
tumour tissues were available and the LOH status remained unclear. According to
these results, it seems that at least certain FH changes might predispose to ovarian
tumours. However, more studies are needed to confirm whether ovarian tumours
should be included in the spectrum of FH mutation associated tumour types.
IV) In this study, a novel variant form of the FH gene was characterized, and the
mRNA expression, translation initiation site and localization of this variant were
determined. The expression of FHv seemed to be induced in unfavorable growth
conditions which might suggest that it has a role e.g. in energy production or in
the adaptation of the cell to disadvanteous environments. Currently, however, the
physiological relevance of FHv remains obscure.
This thesis work defined the roles of two TCAC associated genes in several tumour
types. Alterations in the SDHB and FH genes were observed in novel tumour types,
which provide new information for both researchers and clinicians. In addition, the
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characterization of FHv provided new information concerning this novel cancer
predisposing gene. However, more investigations are needed to determine the additional
functions of FH and FHv and to clarify the link between FH and tumourigenesis.
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